var title_f25_47_26352="Simplified current view BMPR-II";
var content_f25_47_26352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Signal transduction of the TGF-&beta; superfamily",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A negative feedback loop is generated by the transcription of the inhibitory Smads by signaling from TGF-&beta; family of ligands (Smad6 preferentially inhibits the BMP/Smad1 pathways, whereas Smad7 appears to act as a more general inhibitor, at least in part by associating with activated type 1 receptors to prevent R-Smad binding). The orphan receptors ALK-1 and ALK-7 are illustrated at the site of their known Smad interactions. For clarity, many other regulatory and interacting pathways are not illustrated.",
"    <div class=\"footnotes\">",
"     * Endoglin interacts with several receptors.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Wilkins, MR, Gibbs, JS, Shovlin, CL, Lancet 2000: 356:1207. Copyright &copy; 2000 by The Lancet Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26352=[""].join("\n");
var outline_f25_47_26352=null;
var title_f25_47_26353="Herpes simplex keratitis - Dendritic corneal ulceration";
var content_f25_47_26353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex (HSV) keratitis: Dendritic corneal ulceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic dendritic geographic corneal ulceration of HSV keratitis. Stained with fluorescein and Rose Bengal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26353=[""].join("\n");
var outline_f25_47_26353=null;
var title_f25_47_26354="Classic juvenile pityriasis rubra pilaris";
var content_f25_47_26354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Classic juvenile pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classical juvenile-onset pityriasis rubra pilaris (type III), presenting with hyperkeratotic red to orange follicular papules and plaques, with characteristic areas (islands) of uninvolved skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26354=[""].join("\n");
var outline_f25_47_26354=null;
var title_f25_47_26355="Osteomyelitis radiograph MRI";
var content_f25_47_26355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis in a 9-year-old girl with knee pain and fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Plain radiographs of the knee are unremarkable. B) T1 weighted MRI demonstrates marked decrease in signal intensity in the medial metaphysis and epiphysis of the distal femur. There is some involvement of the soft tissue. C) These findings are more pronounced in a T1 weighted MRI with gadolinium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin B Harper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26355=[""].join("\n");
var outline_f25_47_26355=null;
var title_f25_47_26356="Nephrocalcinosis in neonates";
var content_f25_47_26356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephrocalcinosis in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Jodi Smith, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26356/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26356/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26356/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrolithiasis and nephrocalcinosis are common in both term and premature infants who have had difficult neonatal courses. Although multiple factors may contribute (such as high calcium and phosphorous intake [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/1\">",
"     1",
"    </a>",
"    ]), therapy with a loop diuretic appears to be the major risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of nephrocalcinosis in infants with a birth weight below 1500 g may be as high as 64 percent, independent of diuretic use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/4\">",
"     4",
"    </a>",
"    ]. In another study of infants born at less than 32 weeks gestation, 27 percent had nephrocalcinosis; 70 percent of these infants had been treated with a loop diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/5\">",
"     5",
"    </a>",
"    ]. Neonates with prolonged illness are at particular risk, especially those who still require oxygen at 28 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics (with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    being most commonly used) predispose to nephrocalcinosis by increasing urinary calcium excretion. This effect is mediated by inhibition of sodium chloride reabsorption in the thick ascending limb; this is associated with a decline in calcium reabsorption, as calcium transport passively follows that of sodium in this segment. The calciuresis may be prolonged in neonates because there is slower plasma clearance of the diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the increase in urinary calcium excretion, several other factors can promote calcium phosphate precipitation in the tubules and interstitium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics also may increase urinary phosphate excretion, a probable reflection of decreased proximal phosphate reabsorption induced by the mild carbonic anhydrase inhibitory activity of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      There is relative hypercalcemia between 32 and 40 weeks of gestation, a change that may contribute to postnatal hypercalciuria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kidney function is underdeveloped in very low birth weight infants, resulting in hypercalciuria, decreased bicarbonate reabsorptive capacity, a relatively alkaline urine pH (which directly enhances calcium phosphate precipitation), and low urinary citrate excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. Citrate is a potent inhibitor of calcium stone formation, primarily by combining with calcium to form a nondissociable but highly soluble complex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"       \"Risk factors for calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged parenteral nutrition often is required for adequate nutrition, possibly leading to increased urinary oxalate excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concurrent therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , used to treat posthemorrhagic hydrocephalus after intraventricular hemorrhage, diminishes proximal tubular transport of bicarbonate, calcium, and phosphate. The net effect may be increases in urinary calcium and phosphate excretion and an elevation in urine pH. In one report, for example, 7 of 11 infants treated with acetazolamide and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      had hypercalciuria; five of these seven infants had nephrocalcinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal ischemia or the use of nephrotoxic drugs can result in renal tubular injury that can enhance heterogeneous nucleation of calcium phosphate or calcium oxalate crystals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loop diuretic-induced hypercalciuria can be diminished and radiologic appearance of renal calcifications diminished by administrating a thiazide diuretic in place of or alternating with a loop diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible modalities, which have not been well evaluated, include the administration of sodium citrate, potassium citrate, or oral phosphate. The use of citrate therapy has been proposed as a means of preventing nephrocalcinosis. However, in a randomized controlled trial of 74 preterm infants with a gestational age less than 32 weeks, there was no difference in the incidence of nephrocalcinosis between infants who received sodium citrate and control infants (34 versus 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrocalcinosis induced by loop diuretics resolves over time in the majority of infants after cessation of the diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/12,14-19\">",
"     12,14-19",
"    </a>",
"    ]. On the other hand, continued use of a loop diuretic has been associated with lack of resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether nephrocalcinosis affects long-term renal outcome because data are limited and inconsistent.",
"   </p>",
"   <p>",
"    In the largest study of 63 patients born prematurely with nephrocalcinosis and 44 control patients matched for gender, gestational age, and birth weight, there was no difference in serum creatinine levels or estimated glomerular filtration rate (GFR) between the two groups at 3, 6, 12, and 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the mean renal length was shorter in the nephrocalcinosis group. Although patients with nephrocalcinosis had higher urinary calcium-to-creatinine ratios and fractional excretion of uric acid at 12 months of age, there were no differences between the two groups at 24 months of age.",
"   </p>",
"   <p>",
"    Other smaller case series also reported no significant effect on GFR or tubular function when patients were evaluated at school age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other case series observed lower GFR in patients with nephrocalcinosis compared with control patients without nephrocalcinosis. &nbsp;Higher urinary calcium-to-creatinine ratios indicating relative hypercalciuria, decreased tubular phosphate reabsorption, and impaired distal acidification were also reported in patients with nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because it remains unclear whether nephrocalcinosis results in significant chronic renal impairment, continued routine follow-up of affected patients is required to ascertain the long-term renal effect of neonatal nephrocalcinosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF NEPHROCALCINOSIS IN NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three other disorders that should be considered in the infant with nephrocalcinosis: William's syndrome, which also is associated with supravalvular aortic stenosis and hypercalcemia; distal (type 1) renal tubular acidosis; and neonatal primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=see_link\">",
"     \"Williams-Beuren syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the last disorder have hypercalcemia (which is often severe), hypophosphatemia, a normal or increased plasma alkaline phosphatase level, and may present with respiratory distress, failure to thrive, and hypotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/21\">",
"     21",
"    </a>",
"    ]. Rachitic changes often occur and bone x-rays may reveal subperiosteal resorption. At least some cases of neonatal hyperparathyroidism are familial, being results of a homozygous abnormality in the gene for the calcium-sensing protein in the parathyroid gland; heterozygotes have less severe disease and present with asymptomatic hypercalcemia and hypercalciuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hyperprostaglandin E syndrome, a neonatal variant of Bartter syndrome, is another rare cause of hypercalciuria and nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/22\">",
"     22",
"    </a>",
"    ]. This disorder is characterized by increased renal and systemic generation of prostaglandin E, leading to increased bone resorption with enhanced release of calcium into the circulation; diminished tubular calcium reabsorption also may contribute to the elevation in calcium excretion. Long-term therapy with a nonsteroidal antiinflammatory drug improves but does not appear to resolve these abnormalities. However, in one case report of an affected fetus, prenatal treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    prevented the development of severe nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26356/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link&amp;anchor=H3869725#H3869725\">",
"     \"Bartter and Gitelman syndromes\", section on 'Bartter syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is a common complication of preterm infants who require chronic loop diuretic therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to appreciating the contributing role of loop diuretics, the reported incidence of nephrocalcinosis was as high as 64 percent in infants with birth weights below 1500 g. The incidence has decreased substantially with the reduction in the use of loop diuretics.",
"     </li>",
"     <li>",
"      Nephrocalcinosis is due to increased urinary calcium excretion due to a decline of calcium reabsorption, which is associated with inhibition of sodium chloride reabsorption in the thick ascending limb by loop diuretics. Other contributing factors in the preterm infant may include immature renal function, hypercalcemia, and the need for prolonged parenteral nutrition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a neonate with nephrocalcinosis requires diuretic therapy, we recommend that a thiazide agent be used rather than a loop diuretic (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If the infant requires more aggressive diuretic therapy, alternating between a loop and thiazide diuretic agent is an option. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although nephrocalcinosis resolves in the majority of cases, it remains unclear whether nephrocalcinosis results in significant chronic renal impairment. As a result, continued follow-up of affected patients into adulthood is required to ascertain the long-term renal effect of neonatal nephrocalcinosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/1\">",
"      Schell-Feith EA, Kist-van Holthe JE, Conneman N, et al. Etiology of nephrocalcinosis in preterm neonates: association of nutritional intake and urinary parameters. Kidney Int 2000; 58:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/2\">",
"      Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 1982; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/3\">",
"      Glasier CM, Stoddard RA, Ackerman NB Jr, et al. Nephrolithiasis in infants: association with chronic furosemide therapy. AJR Am J Roentgenol 1983; 140:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/4\">",
"      Jacinto JS, Modanlou HD, Crade M, et al. Renal calcification incidence in very low birth weight infants. Pediatrics 1988; 81:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/5\">",
"      Short A, Cooke RW. The incidence of renal calcification in preterm infants. Arch Dis Child 1991; 66:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/6\">",
"      Aranda JV, Lambert C, Perez J, et al. Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 1982; 101:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/7\">",
"      Peterson RG, Simmons MA, Rumack BH, et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/8\">",
"      Adams ND, Rowe JC. Nephrocalcinosis. Clin Perinatol 1992; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/9\">",
"      Itami N, Kawaguti M, Akutsu Y, et al. Renal calcifications in preterm infants. J Pediatr 1989; 114:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/10\">",
"      Sikora P, Roth B, Kribs A, et al. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int 2003; 63:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/11\">",
"      Stafstrom CE, Gilmore HE, Kurtin PS. Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus. Pediatr Neurol 1992; 8:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/12\">",
"      Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 1988; 113:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/13\">",
"      Schell-Feith EA, Moerdijk A, van Zwieten PH, et al. Does citrate prevent nephrocalcinosis in preterm neonates? Pediatr Nephrol 2006; 21:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/14\">",
"      Downing GJ, Egelhoff JC, Daily DK, Alon U. Furosemide-related renal calcifications in the premature infant. A longitudinal ultrasonographic study. Pediatr Radiol 1991; 21:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/15\">",
"      Downing GJ, Egelhoff JC, Daily DK, et al. Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years. J Pediatr 1992; 120:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/16\">",
"      Kist-van Holthe JE, van Zwieten PH, Schell-Feith EA, et al. Is nephrocalcinosis in preterm neonates harmful for long-term blood pressure and renal function? Pediatrics 2007; 119:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/17\">",
"      Porter E, McKie A, Beattie TJ, et al. Neonatal nephrocalcinosis: long term follow up. Arch Dis Child Fetal Neonatal Ed 2006; 91:F333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/18\">",
"      Jones CA, King S, Shaw NJ, Judd BA. Renal calcification in preterm infants: follow up at 4-5 years. Arch Dis Child Fetal Neonatal Ed 1997; 76:F185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/19\">",
"      Hoppe B, Duran I, Martin A, et al. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol 2002; 17:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/20\">",
"      Giapros V, Tsoni C, Challa A, et al. Renal function and kidney length in preterm infants with nephrocalcinosis: a longitudinal study. Pediatr Nephrol 2011; 26:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/21\">",
"      Orwoll E, Silbert J, McClung M. Asymptomatic neonatal familial hypercalcemia. Pediatrics 1982; 69:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/22\">",
"      Leonhardt A, Timmermanns G, Roth B, Seyberth HW. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 1992; 120:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26356/abstract/23\">",
"      Konrad M, Leonhardt A, Hensen P, et al. Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes. Pediatrics 1999; 103:678.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6125 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26356=[""].join("\n");
var outline_f25_47_26356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER CAUSES OF NEPHROCALCINOSIS IN NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26357="Electroanatomic atrial tachy II";
var content_f25_47_26357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75508%7ECARD%2F55564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75508%7ECARD%2F55564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic map of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The activation map, in the right anterior oblique projection, was obtained by electroanatomic mapping during atrial tachycardia. The earliest activation, shown in red (arrow), represents the origin of the tachycardia located in the posterolateral right atrium in the region of the crista terminalis. The impulse spreads from this focus (yellow to green to blue), to activate the rest of the right atrium. The last part to be activated is the region around the superior vena cave (SVC) (deep blue).",
"    <div class=\"footnotes\">",
"     TA: tricuspid annulus; IVC: inferior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Marchlinski, F, Callans, D, Gottleib, C, et al, Pacing Clin Electrophysiol 1998; 21:1621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic map of focal right atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color-coded activation isochrones generated during an ectopic or focal atrial tachycardia show that the earliest activation, relative to a remote fiducial point, is the lower part of the right atrium, represented by red color. The spread of activation is centrifugal from a focal point located along the distal crista terminalis and goes from the lowest part towards the top of the right atrium (blue color).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hasan Garan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26357=[""].join("\n");
var outline_f25_47_26357=null;
var title_f25_47_26358="Overview of tibial fractures in adults";
var content_f25_47_26358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of tibial fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26358/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26358/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the tibia may result from significant trauma or be the consequence of repetitive use. The latter mechanism leads to stress fractures. An overview of traumatic tibial fractures in adults is presented here. Stress fractures, pediatric fractures of the tibia, and general fracture assessment and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link\">",
"     \"Overview of tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link\">",
"     \"General principles of fracture management: Bone healing and fracture description\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=see_link\">",
"     \"General principles of definitive fracture management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial fractures occur in both high energy trauma, such as motor vehicle and cycling accidents, and low energy trauma, such as falls, contact sports, distance running, and other endurance or repetitive impact activities. Injuries caused by high energy trauma are more likely to involve complex and open tibia fractures; injuries caused by low energy trauma more often result in simple transverse or linear tibia fractures. Open fractures of the tibia have high rates of complications and long term problems with limitations of function and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults and children, closed tibial shaft fractures are the most common long-bone fractures. With greater than 70,000 hospitalizations, 800,000 office visits, and 500,000 hospital days, they have major economic consequences. The elderly suffer many of these fractures from simple falls, and those with significant osteoporosis incur open or more complex fractures, often with high morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tibia fractures occur during contact and noncontact sporting events. Several studies demonstrate that a direct, low velocity blow (eg, tackling, kicking) causes approximately 95 percent of sports-related tibial fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/3\">",
"     3",
"    </a>",
"    ]. In one five year retrospective study of 244 tibial fractures seen at a major trauma center, 24 (9.8 percent) occurred during football (ie, soccer) games [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/4\">",
"     4",
"    </a>",
"    ]. Even when low energy trauma is the cause, concomitant fibular fractures develop in approximately 60 percent of cases. Nevertheless, significant complications develop in fewer than five percent of sports-related tibial fractures and the prognosis is generally good.",
"   </p>",
"   <p>",
"    Avulsion fractures of the lateral and medial tibia may have diagnostic significance in looking for ACL or PCL ligament injuries. The Segond fracture occurs just below the iliotibial band attached to the fibers of the lateral capsule and is associated with ACL tear. Proximal tibial avulsion fractures at the medial aspect of the bone may be a marker of PCL injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of tibia fractures among football (soccer) players appears to be declining, although the reasons for this remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ]. Some claim that increased use of shin guards accounts for the decline. However, studies of other contact sports and a case series in which 85 of 100 football-related tibia fractures where sustained by athletes wearing shin guards argue against this claim. Case reports suggest that tibial fractures are occurring in snowboarding, mixed martial arts, and &ldquo;X-game&rdquo; type sports (eg, skateboarding), although demographic data is scant.",
"   </p>",
"   <p>",
"    Long term bisphosphonate use, particularly in elder patients, may contribute to tibial fractures . Case reports document insufficiency type fractures of the tibia without known trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H50#H50\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Atypical femur fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the tibia in adults are classified clinically based upon their location. Fractures of the proximal tibia are subclassified into those affecting the tibial plateau or the intercondylar notch and avulsion fractures of the tibial tubercle. Researchers use a more complex classification system known as the Arbeitsgemeinschaft",
"    <span class=\"nowrap\">",
"     Osteosynthesefragen/Association",
"    </span>",
"    for the Study of Internal Fixation",
"    <span class=\"nowrap\">",
"     (AO/ASIF)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Locations of fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to the different locations of tibial fractures are discussed separately in the appropriate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal tibial fractures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link\">",
"       \"Proximal tibial fractures in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tibial shaft fractures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30790?source=see_link\">",
"       \"Tibial shaft fractures in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Distal tibial and medial malleolus fractures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=see_link\">",
"       \"Overview of ankle fractures in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"UTD.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"UTD.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The proximal portion of the bone, the tibial plateau, forms the lower surface of the knee joint. The tibial plateau consists of the medial tibial condyle, the thicker of the two articular surfaces, and the lateral tibial condyle, a relatively thinner and weaker portion of the joint. Separating the medial from the lateral condyle is the intercondylar eminence, an important bony prominence that anchors the attachment of the anterior cruciate ligament. The tibial shaft bridges the distance to the distal tibia which contributes the superior articular surface of the ankle joint at the tibiotalar articulation as well as the medial malleolus. Another key bony landmark is the tibial tuberosity, which sits several centimeters below the joint line and the inferior patellar pole, and serves as the attachment site for the patellar tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strong fibrous structure, the interosseous membrane, connects the tibia and fibula along the length of the two bones. Proximally, this structure is reinforced by strong anterior and posterior ligaments and forms a synovial joint known as the proximal tibiofibular articulation. Distally, the interosseous membrane and three ligaments, the anterior, posterior, and transverse tibiofibular ligaments, stabilize the superior ankle joint. Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg. Fascial extensions and the interosseous membrane separate the muscles, nerves, and vessels of the lower leg into four distinct compartments. Three of these, the anterior, posterior, and deep posterior compartments, all border the tibia and can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Nerves and vessels lie within the anterior and the deep posterior compartments, and trauma that causes significant swelling in these compartments can result in neurovascular compromise (",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"UTD.htm?4/40/4740\">",
"     figure 1",
"    </a>",
"    ). The key blood supply of the tibia arises from periosteal vessels and the nutrient artery. The nutrient artery originates from the posterior tibial artery and enters the posterolateral cortex at the middle third of the tibial shaft near the origin of the soleus muscle. Fractures in this region potentially compromise this blood supply. The periosteal vessels provide a less vulnerable circulation as they derive an abundant blood supply from the anterior tibial artery which travels down along the interosseous membrane. Vascular compromise can arise more proximally from marked effusion of the knee joint, from trauma that affects the popliteal artery before it branches into the anterior and posterior tibial arteries, or at the level of the anterior tibial artery as it branches off the popliteal artery and passes through a gap in the interosseous membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tibial nerve and several branches provide the key innervation to the muscles of the lower leg and foot. Nerve roots arise from L4 through S3. The posterior tibial nerve parallels the course of the posterior tibial artery and courses through the deep posterior compartment. In the popliteal space branches of the tibial nerve provide innervation to the posterior compartment and to the popliteus muscle. The deep peroneal nerve branches and follows the course of the anterior tibial artery providing innervation to muscles in the anterior lower leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The injured leg is examined for localized swelling, shortening, and angulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin is inspected for evidence of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ecchymosis",
"     </li>",
"     <li>",
"      Lacerations",
"     </li>",
"     <li>",
"      Puncture wounds or evidence of secondary infection",
"     </li>",
"     <li>",
"      Protrusion of bone fragments indicative of a compound fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If medicolegal considerations warrant, photographs of the injury may be taken with the patient's permission. Wound and blood cultures should be obtained prior to initiating antibiotic therapy if there are signs of soft tissue infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ligamentous and meniscal integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligamentous and meniscal injuries frequently occur in conjunction with proximal tibial fractures. Instillation of local anesthetic into the knee joint is sometimes necessary to allow testing (eg, McMurray, Lachman, collateral ligament stressing). Varus or valgus stress that leads to more than 10 degrees of opening is abnormal and, if inferior to the joint line, suggests a displaced fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurovascular integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct damage to neurovascular structures may occur with tibial fractures. It is appropriate to test skin sensation, muscle function, distal pulses, and capillary refill to determine the integrity of the nerves and arterial supply to the lower limb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial fractures, particularly open or complex injuries, often involve complications, which may include acute compartment syndrome, neurovascular injuries, and infection. Fat emboli may complicate any type of tibial fracture, ranging from complex fractures treated surgically to simple fractures treated nonoperatively. Although tibial fractures due to low energy mechanisms, such as those sustained during sports, have lower complication rates, even these are susceptible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated pressure due to increased volume within a constricting fascia can cause an acute compartment syndrome, which can threaten the limb and constitutes a surgical emergency. Bleeding from a tibial fracture can extravasate into the posterior, deep posterior, or anterior compartment (",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"UTD.htm?4/40/4740\">",
"     figure 1",
"    </a>",
"    ) and elevate the intracompartmental pressure. Involvement of the lateral compartment usually implies that a fibular injury is also present. Acute compartment syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tense swelling of the affected muscles, decreased distal pulses, muscle weakness, increased pain elicited by passive stretch of involved muscles, and impaired sensation due to nerve compression or ischemia may be noted on examination. This may progress to pulselessness, paralysis, and anesthesia. Permanent neuromuscular damage may ensue if the compartment pressure is not decreased promptly by fasciotomy.",
"   </p>",
"   <p>",
"    Runners can present with both lower leg pain and injuries that cause a compartment syndrome in the absence of a fracture. Similar symptoms may also accompany or be confused with the shin splint syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H957904#H957904\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Chronic exertional compartment syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6199304\">",
"    <span class=\"h2\">",
"     Long-term calf atrophy and sport limitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial shaft fractures treated with casting may lead to long term muscle atrophy of the posterior compartments of the calf. One observational study reevaluated 23 patients who at an average age of 18 sustained a tibial shaft fracture treated with cast immobilization for an average of 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/13\">",
"     13",
"    </a>",
"    ]. Sixteen years after the initial injury, CT examination revealed significant calf muscle atrophy. Only 3 of the 23 returned to their previous level of competitive sport, while 10 of 23 returned to recreational sport at a lower level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6199311\">",
"    <span class=\"h2\">",
"     Long-term function and arthritis risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have sought to evaluate the development of significant osteoarthritis following treatment of tibial fractures. As expected, more severe injuries are associated with a higher risk of osteoarthritis and disability.",
"   </p>",
"   <p>",
"    An observational study of 44 patients with tibial spine fractures that were diagnosed at a mean age of 24 and required internal fixation reported minimal arthritis and good function at follow-up (mean 16 years, range 5 to 27 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/14\">",
"     14",
"    </a>",
"    ]. According to several observational studies, younger patients with tibial plateau fractures managed surgically appear to retain good knee and leg function at five-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26358/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One study with follow up of 5 to 27 years showed mild to moderate arthritis in 31 percent of patients with monocondylar injuries, but more severe arthritis in patients who had 5 or more degrees of malalignment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiographs are the basic means to assess tibial shaft fractures. Initial studies include anteroposterior (AP) and lateral views. These should incorporate the entire length of the lower leg from knee to ankle. Radiolucent splinting during the procedure reduces the risk of additional injury and allows proper positioning to best visualize fractures.",
"   </p>",
"   <p>",
"    Important features that can be assessed from the plain radiographs are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture location and type (eg, transverse, oblique, comminuted)",
"     </li>",
"     <li>",
"      Displacement",
"     </li>",
"     <li>",
"      Angulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nondisplaced fractures of the tibia have &le;5 mm of displacement and &lt;10 degrees of angulation or rotation.",
"   </p>",
"   <p>",
"    CT scans and MRI are reserved for more complex injuries. MRI has particular value in higher tibial fractures that may extend into the knee joint or are suspected of involving the tibial plateau. MRI also helps delineate associated meniscal or ligamentous injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles of fracture management apply to tibial fractures. Management of specific tibial fractures varies with the anatomic location of the fracture and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link\">",
"     \"Proximal tibial fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30790?source=see_link\">",
"     \"Tibial shaft fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following steps should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimize further tissue injury, particularly of neural and vascular structures, by immobilizing the fracture. Because substantial soft tissue swelling can occur, initial immobilization is generally achieved by applying a removable plaster or fiberglass splint. The splint will later be removed to allow reduction, fixation, or replacement with a better fitting cast.",
"     </li>",
"     <li>",
"      Apply ice to minimize swelling and inflammation",
"     </li>",
"     <li>",
"      Elevate the injured extremity.",
"     </li>",
"     <li>",
"      Give analgesics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients achieve adequate pain relief from immobilization, ice, and over-the-counter analgesics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    . Opioid analgesics are occasionally needed to control pain during the first three to five days. Patients requesting opioids beyond this time should be reevaluated for irritation from a poorly fitting splint, a missed secondary injury, or a fracture complication.",
"   </p>",
"   <p>",
"    Patients with tibial fractures awaiting urgent surgical intervention should be managed with splinting, ice, and non-opioid analgesics (if possible) until they have made a decision about surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"       \"Patient information: Shinbone fracture (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       \"Patient information: Fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Closed tibial shaft fractures are the most common long-bone fractures. Tibial fractures occur in both high energy trauma, such as motor vehicle and cycling accidents, and low energy trauma, such as falls, contact sports, distance running, and other endurance or repetitive impact activities. Injuries caused by high energy trauma are more likely to involve complex fractures and complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fractures of the tibia in adults are classified clinically based upon their location. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.) Each type is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link\">",
"       \"Proximal tibial fractures in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30790?source=see_link\">",
"       \"Tibial shaft fractures in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=see_link\">",
"       \"Stress fractures of the tibia and fibula\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=see_link\">",
"       \"Overview of ankle fractures in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A careful examination of the injured extremity includes an assessment of neurovascular function, leg deformity, skin integrity, and joint stability (if possible). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tibial fractures, particularly open or complex injuries, often involve complications, which may include acute compartment syndrome, neurovascular injuries, infection, and fat emboli. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain film radiographs are the basic means to assess tibial shaft fractures. Initial studies include anteroposterior (AP) and lateral views. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of tibial fractures includes immobilization, analgesics, elevation, and ice. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/1\">",
"      Kohlprath R, Assal M, U&ccedil;kay I, et al. [Open fractures of the tibia in the adult: surgical treatment and complications]. Rev Med Suisse 2011; 7:2482, 2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/2\">",
"      Schmidt AH, Finkemeier CG, Tornetta P 3rd. Treatment of closed tibial fractures. Instr Course Lect 2003; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/3\">",
"      Cattermole HR, Hardy JR, Gregg PJ. The footballer's fracture. Br J Sports Med 1996; 30:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/4\">",
"      Chang WR, Kapasi Z, Daisley S, Leach WJ. Tibial shaft fractures in football players. J Orthop Surg Res 2007; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/5\">",
"      Kaneko K, Miyazaki H, Yamaguchi T. Avulsion fracture of the tibial tubercle with avulsion of the patellar ligament in an adolescent female athlete. Clin J Sport Med 2000; 10:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/6\">",
"      Peterson CM, Gittins ME. Tibial tuberosity avulsion in an adolescent diver. Clin J Sport Med 1997; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/7\">",
"      Inoue G, Kuboyama K, Shido T. Avulsion fractures of the proximal tibial epiphysis. Br J Sports Med 1991; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/8\">",
"      Biedert RM, Friederich N, M&uuml;ller W. Medial Tibial Avulsion Fragment: Corresponding Lesion to Segond's Fracture? Clin J Sport Med 1994; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/9\">",
"      Lenehan B, Fleming P, Walsh S, Kaar K. Tibial shaft fractures in amateur footballers. Br J Sports Med 2003; 37:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/10\">",
"      Tang ZH, Kumar VP. Alendronate-associated ulnar and tibial fractures: a case report. J Orthop Surg (Hong Kong) 2011; 19:370.",
"     </a>",
"    </li>",
"    <li>",
"     Muller ME, Nararin S, Koch P, et al. Comprehensive Classification of Fracture of Long Bones, Springer-Verlag, Berlin 1990.",
"    </li>",
"    <li>",
"     Duke Orthopaedics. Tibia fracture. In: Wheeless' Textbook of Orthopedics. file://www.wheelessonline.com/ortho/menu_for_the_tibia_tibia_frx (Accessed on March 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/13\">",
"      Khalid M, Brannigan A, Burke T. Calf muscle wasting after tibial shaft fracture. Br J Sports Med 2006; 40:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/14\">",
"      Rademakers MV, Kerkhoffs GM, Kager J, et al. Tibial spine fractures: a long-term follow-up study of open reduction and internal fixation. J Orthop Trauma 2009; 23:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/15\">",
"      Stevens DG, Beharry R, McKee MD, et al. The long-term functional outcome of operatively treated tibial plateau fractures. J Orthop Trauma 2001; 15:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26358/abstract/16\">",
"      Rademakers MV, Kerkhoffs GM, Sierevelt IN, et al. Operative treatment of 109 tibial plateau fractures: five- to 27-year follow-up results. J Orthop Trauma 2007; 21:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 251 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26358=[""].join("\n");
var outline_f25_47_26358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Locations of fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin integrity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ligamentous and meniscal integrity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurovascular integrity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6199304\">",
"      Long-term calf atrophy and sport limitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6199311\">",
"      Long-term function and arthritis risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/251|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/40/4740\" title=\"figure 1\">",
"      Cross section lower leg",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/251|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=related_link\">",
"      General principles of definitive fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=related_link\">",
"      General principles of fracture management: Bone healing and fracture description",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=related_link\">",
"      Overview of ankle fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=related_link\">",
"      Overview of tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=related_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=related_link\">",
"      Proximal tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=related_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30790?source=related_link\">",
"      Tibial shaft fractures in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26359="Preventing postoperative peritoneal adhesions";
var content_f25_47_26359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preventing postoperative peritoneal adhesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Alan H DeCherney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Senthil Kumar, MS, FRCS (Ed), FRCS (Gen Surg)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26359/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesions resulting from surgical procedures can cause considerable pain, make reoperation difficult, cause bowel obstruction and impair fertility in women.",
"   </p>",
"   <p>",
"    A number of human interventional trials and animal studies have evaluated techniques and materials designed to prevent and reduce postsurgical adhesions. The results have been inconclusive and sometimes contradictory. Thus, preventing postsurgical adhesions remains an art, rather than a science. The epidemiology, pathogenesis and approach and importance to preventing adhesion are discussed here.",
"   </p>",
"   <p>",
"    The management of postoperative pain, small bowel obstruction and infertility are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND BURDEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies illustrate the frequency and significant consequences of postoperative adhesions, and the need for effective strategies to prevent them.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the Scottish National Health Service Medical Record Linkage Database was used to select a cohort of 8849 women who underwent open gynecological surgery in 1986, and then all of their readmissions in the subsequent 10 years were reviewed for potential adhesion related disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/1\">",
"       1",
"      </a>",
"      ]. The rate of readmission directly related to adhesions was",
"      <span class=\"nowrap\">",
"       2.9/100",
"      </span>",
"      initial operations, and ovarian surgery had the highest rate directly related to adhesions",
"      <span class=\"nowrap\">",
"       (7.5/100",
"      </span>",
"      initial operations). With the exception of laparoscopic sterilizations, open and laparoscopic gynecological surgery were associated with comparable risks of adhesion-related readmissions [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of female patients with a diagnosis of small-bowel obstruction (SBO) between 1989 and 1996, the incidence of SBO after an abdominal hysterectomy was 16.3 per 1000 hysterectomies, but after cesarean delivery it was only 5 per 10,000 cesarean deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/3\">",
"       3",
"      </a>",
"      ]. The median interval between the initial operation and the small-bowel obstruction was 5.3 years. These rates were similar when analyzed for the 1998 to 2005 time period [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among infertile women with adnexal adhesions, pregnancy rates were lower in women with untreated adhesions than in those who underwent adhesiolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/5\">",
"       5",
"      </a>",
"      ]. Pregnancy rates in control and treated patients were 11 and 32 percent, respectively after 12 months and 16 and 45 percent, respectively, after 24 months.",
"     </li>",
"     <li>",
"      The relationship between chronic pelvic pain and presence of adhesions is poorly defined. There is some evidence that dense adhesions that limit organ mobility cause visceral pain [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of chronic pelvic pain in women\", section on 'Adhesions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF ADHESION FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several factors involved in mechanisms of adhesion formation. Damage to peritoneal surfaces induces a repair response, which consists of an inflammatory process involving fluid, neutrophils, leukocytes, macrophages, cytokines, mesothelial cells, and tissue and coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/7\">",
"     7",
"    </a>",
"    ]. The inflammatory response results in fibrin deposition at the site of injury within three hours of the tissue trauma and peaking on postoperative day 4 to 5. If complete fibrinolysis and resorption of degradation products subsequently occur, reepithelialization will result in a smooth healed tissue surface. However, if this process is disturbed, connective tissue scars and adhesions develop from in growth of fibroblasts, capillaries, and nerves. Fibrinolysis may be impaired by thermal injury, desiccation, ischemia, foreign bodies, blood, bacteria, and some drugs; genetic polymorphisms may also play a role in the host's inflammatory and healing response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACH TO PREVENTION OF ADHESION FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental actions for the prevention of adhesions are directed at the mechanisms of adhesion formation and include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limiting or preventing the initial peritoneal injury",
"     </li>",
"     <li>",
"      Preventing coagulation of the serous exudate",
"     </li>",
"     <li>",
"      Removing or dissolving the deposited fibrin",
"     </li>",
"     <li>",
"      Keeping the fibrin-coated peritoneal surfaces separated",
"     </li>",
"     <li>",
"      Inhibiting the fibroblastic response to the tissue injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good surgical technique is the first defense against adhesion formation as meticulous hemostasis and gentle, minimal tissue handling are critical for limiting the initial peritoneal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/6\">",
"     6",
"    </a>",
"    ]. Laparoscopic surgery can be associated with less tissue damage than laparotomy, thereby reducing the risk of adhesion formation, especially to the abdominal wall. Advantages of laparoscopy are that the abdominal incisions are small, there is less handling of tissue and exposure to foreign bodies, and fewer postoperative infections occur. However, the laparoscopic approach does not guarantee the absence of adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/9\">",
"     9",
"    </a>",
"    ], and long duration of surgery and high insufflation pressures can increase the risk of adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serosal damage can be prevented by minimizing trauma, bleeding, and ischemia and by keeping the surgical field free of desiccation by frequent irrigation. Traditional laparotomy sponges can be abrasive and should be avoided. Many pelvic surgeons place these sponges in sterile plastic bags, thus preventing the braided cloth from touching the peritoneal lining when packing is required. In addition, removing the talc or starch from gloves prior to entering the peritoneal cavity is a simple, but often neglected measure that eliminates a source of irritation that can lead to adhesion formation. Introduction of potentially reactive foreign bodies (eg, excess suture material, lint, talc) should be minimized to reduce the number of niduses for fibrin deposition. Fine, nonreactive suture material should be used.",
"   </p>",
"   <p>",
"    Reapproximation of peritoneal defects does not appear to prevent adhesions after reproductive surgery performed via laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The incidence of adhesions is similar whether or not the peritoneum is reapproximated. We do not routinely reapproximate parietal peritoneum, but when suturing is necessary, we use fine resorbent material that incites the least amount of tissue reactivity, such as polyglactin instead of chromic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical barriers and pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barriers and pharmacologic agents are two methods traditionally employed to prevent adhesions, in combination with meticulous surgical technique. Barriers may be either fluid or solid, and the latter can be absorbable or nonabsorbable. Future molecular interventions at the level of the fibrin clot may involve recombinant tissue plasminogen activator and novel fibrinolytics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL BARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of physical barriers to reduce postsurgical adhesions is not without risk or cost. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     oxidized regenerated cellulose",
"    </a>",
"    , hyaluronic acid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    , and expanded polytetrafluoroethylene, all prolong operative time. This directly results in increased hospital cost, which is compounded further by the cost of the product itself, for an estimated total of $400 to $700 per procedure. If these barriers accomplish what they are designed to do, however, the avoidance of future adhesiolytic surgery outweighs these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sheets",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Oxidized regenerated cellulose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     Oxidized regenerated cellulose",
"    </a>",
"    (ORC) is a commonly employed absorbable adjuvant. This material creates a temporary barrier that prevents adhesions when applied to traumatized tissue. Initial studies using Surgicel (Ethicon, Inc), an earlier version of the product with a loose weave, were inconclusive but suggested some benefit. The knit of the ORC barrier was subsequently modified to create Interceed, the ORC product in current use. This material is more effective in reducing postsurgical adhesions because it is absorbed over a longer interval, presumably allowing sufficient time for fibrin-clot dissolution and reepithelialization of the traumatized peritoneum.",
"   </p>",
"   <p>",
"    The efficacy of ORC for postsurgical adhesion prevention was illustrated by a systematic review that compared ORC to no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/13\">",
"     13",
"    </a>",
"    ]. Use of this barrier at laparoscopy significantly reduced the incidence of new adhesions (OR 0.31, 95% CI 0.12-0.79) and reformation of adhesions (OR 0.19, 95% CI 0.09- 0.42). The agent was similarly effective when used at laparotomy. These studies established Interceed's efficacy in connection with microsurgical technique and specifically addressed the issue of ovarian, tubal, uterine, and colonic adhesions to the pelvic sidewall. However, an effect on subsequent pregnancy rates has not been established.",
"   </p>",
"   <p>",
"    Interceed is available in sheets measuring 1.5 x 2 inches or 3 x 4 inches. The smaller size is appropriate for laparoscopic placement. The barrier is degraded and absorbed with two weeks of application. Placement requires several steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operative site must be hemostatic and free of blood, which prevents the barrier from functioning.",
"     </li>",
"     <li>",
"      All excess fluid must be removed from the peritoneal cavity by gentle aspiration after placing the patient in a reverse Trendelenburg position.",
"     </li>",
"     <li>",
"      The Interceed barrier must completely cover the affected area of the operative site and should be moistened gently with sterile irrigant to help maintain its position. Suturing is not needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hyaluronic acid sheets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest hyaluronic acid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    (Seprafilm) may decrease the extent of adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/13\">",
"     13",
"    </a>",
"    ] and SBO due to adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/14\">",
"     14",
"    </a>",
"    ]. Further study is required. In one randomized trial, the proportion of patients who were adhesion free at follow-up laparoscopy was 48 percent for Seprafil versus 31 percent in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyaluronic acid with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    is available in 5 x 6 inch sheets. It is a brittle film that has a tendency to fracture when bent at sharp angles, thus making it unsuitable for laparoscopic use. The desired shape is cut and applied with clean instruments over the surgical site. Care should be taken to avoid touching viscera and other tissues prior to final placement. Instrument manipulation is preferred to manual application because the membrane can stick to gloves and become displaced. The paper backing on the film is then removed carefully, keeping the membrane at the operative site. Suturing is not needed. The transparent, absorbable membrane lasts for seven days, during which time it prevents coaptation of traumatized tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Expanded polytetrafluoroethylene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expanded polytetrafluoroethylene (ePTFE, Gore-Tex Surgical Membrane) membrane is a nonabsorbable, flexible barrier. It has been used extensively as a substitute for pericardium in cardiac surgery because of its nonreactivity, strength, and pliability.",
"   </p>",
"   <p>",
"    One randomized clinical trial involving 32 patients directly compared ePTFE and ORC in pelvic reconstructive surgery by placing ePTFE on one sidewall and ORC on the other [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/16\">",
"     16",
"    </a>",
"    ]. Twenty-nine patients underwent second-look laparoscopy. Both ORC and ePTFE resulted in improved adhesion scores and reduced the area of adhesions, but ePTFE was associated with the most benefit (",
"    <a class=\"graphic graphic_figure graphicRef56961 \" href=\"UTD.htm?38/41/39581\">",
"     figure 1",
"    </a>",
"    ). More sidewalls covered with PTFE had no adhesions (21 versus 7) and the number of sidewalls without adhesions was greater with PTFE coverage than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     oxidized regenerated cellulose",
"    </a>",
"    coverage (16 versus 2). The ePTFE membrane was removed at laparoscopy in all patients who underwent a successful second-look procedure (29 of 32 patients).",
"   </p>",
"   <p>",
"    Another randomized study of 28 patients who underwent myomectomy at the time of exploratory laparotomy sutured ePTFE over the uterine incision site or used no barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/17\">",
"     17",
"    </a>",
"    ]. At second-look laparoscopy, more patients receiving ePTFE were adhesion-free than controls (55 versus 7 percent).",
"   </p>",
"   <p>",
"    There are no long-term data regarding complications or pregnancy rates in ePTFE treated patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ePTFE is trimmed to cover the deperitonealized area by 1 cm and affixed with nonabsorbable sutures, usually a 7-0 or 8-0 nylon or polypropylene. Patients should be asked to sign an informed consent form if the barrier is to be retained in situ, or else it can be removed at a later date. The long-term effects of leaving a nonabsorbable barrier in the pelvis are unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Polyethylene glycol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyethylene glycol (Spraygel) adhesion barrier is a synthetic hydrogel that forms within seconds of spraying two solutions of polyethylene glycol-based (PEG) liquids concomitantly onto targeted tissue. Crosslinks between the solutions form an absorbable, flexible, adherent gel barrier, which remains intact for five to seven days before breaking down to its PEG components, which are then resorbed and excreted by the kidneys. A randomized trial comparing use of this agent to placebo in women undergoing myomectomy demonstrated a &gt;60 percent reduction in adhesion score at second look laparoscopy in treated patients, with no adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/18\">",
"     18",
"    </a>",
"    ]. Spraygel is available in Europe, but is awaiting evaluation by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Instillates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found no statistically significant benefit from use of intraoperative irrigation or infusion of various drugs and liquids, including intraperitoneal steroids (1 trial, 61 subjects),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    (2 trials, 210 subjects),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    (1 trial, 53 subjects), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (1 trial, 63 subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/19\">",
"     19",
"    </a>",
"    ]. The small number of studies and subjects preclude definitive conclusions. Antibiotic solutions are also ineffective in prevention of adhesions. In rats,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    irrigation of the abdominal cavity actually contributed to the formation of peritoneal adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, instillation of fluid into the peritoneal cavity at the termination of surgery is associated with many theoretical and practical concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. Fluid overload can lead to pulmonary edema, many patients complain of abdominal pain and dyspnea, and it is common to have leakage through the laparoscopic sites, which is distressing to the patient, requires frequent bandage replacement, and prompts frequent calls to the physician. Extravasation to the vulvar area has been reported in up to 2 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    70 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peritoneal-fluid residence time has been serially evaluated by both ultrasound and daily weight measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Crystalloid instillation is associated with an increased body weight for up to 24 hours postoperatively. On ultrasound examination, the residual peritoneal fluid volume resulting from crystalloid infusion was no different from controls (who received no fluid) at 24 hours. However, patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    70 had greater peritoneal fluid, as measured by ultrasound, through the third postoperative day, with no significant differences noted on days 4 through 7. Daily weight also increased up to day 4 in the dextran-treated group.",
"   </p>",
"   <p>",
"    The increase in intraperitoneal fluid leads to a theoretical concern of decreased opsonization of foreign cells and impairment of host-cell phagocytosis. In the rat model, increasing the inoculum from I mL to 10 mL increases its lethality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/20\">",
"     20",
"    </a>",
"    ]. Therefore, leaving large volumes of fluid within the peritoneal cavity, as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , may result in untoward infectious sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Icodextrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 4% non-viscous, isosmolar solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    (eg, Adept&reg;), an alpha-1,4 glucose polymer with prolonged intraperitoneal residence is the most promising intraoperative instillate for adhesion prevention. It is used following laparoscopic adhesiolysis and is the only agent approved by the FDA for preventing adhesions in gynecological laparoscopic procedures.",
"   </p>",
"   <p>",
"    A multicenter, prospective, randomized, double-blind trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    to lactated Ringer's solution in 402 women undergoing laparoscopic gynecological surgery involving adhesiolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/27\">",
"     27",
"    </a>",
"    ]. The incidence, severity, and extent of adhesions were evaluated at initial laparoscopy and at follow-up laparoscopy four to eight weeks later. Significantly more patients in the icodextrin group achieved a reduction in adhesions of at least three or 30 percent of sites lysed (49 percent versus 38 percent in controls). In infertility patients, more patients in the icodextrin group had a reduction in their American Fertility Society (AFS) adhesion score (53 versus 30 percent) and fewer icodextrin patients had a",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    AFS score (14 versus 43 percent). Safety was comparable in both groups. Transient labial edema occurred in some patients who received icodextrin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     Icodextrin",
"    </a>",
"    4% is used as an irrigant during surgery (minimum 100",
"    <span class=\"nowrap\">",
"     mL/30",
"    </span>",
"    minutes) and then, at the end of the procedure, all the irrigant is removed and 1000 mL of fresh icodextrin 4% is instilled into the peritoneal cavity and left as a fluid reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/27\">",
"     27",
"    </a>",
"    ]. It is slowly absorbed by the lymphatic system and broken down into amylase and metabolized to glucose (40 g per liter of instillate) over a period of up to four days. Thus, it acts to separate traumatized tissue surfaces during the critical period of healing and adhesion formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hyaluronic acid solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials of hyaluronic acid-containing solutions found that use of these agents significantly reduced the proportion of adhesions (women with adhesions or the extent of adhesions) at second look laparoscopy (PR 0.31, 95% CI 0.19-0.51) and the number of women with deterioration of adhesion score (OR 0.28, 95% CI 0.12-0.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/28\">",
"     28",
"    </a>",
"    ]. However, there was no significant change in the mean adhesion score; subsequent pregnancy rates were not evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SYSTEMIC DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some nonsteroidal antiinflammatory drugs (NSAIDs) may play a role in adhesion prevention. There are no prospective, randomized, clinical trials of NSAIDs for this purpose involving humans, but there is evidence from animal studies that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    and interleukin 10 and interleukin 4 are efficacious in reducing adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoids, promethazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials comparing use of glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    versus no treatment for adhesion prevention after gynecological surgery found no evidence of a beneficial effect of drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26359/abstract/19\">",
"     19",
"    </a>",
"    ]. The small number of studies and subjects preclude definitive conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative adhesions are the result of tissue trauma and subsequent healing. They may lead to pain, infertility, or bowel obstruction, and increase the difficulty and morbidity of subsequent surgical procedures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis of adhesion formation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and burden'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest meticulous surgical technique as the first defense against adhesion formation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopy generally results in less tissue damage than laparotomy and thus reduces the risk of adhesion formation. However, it does not guarantee the absence of adhesions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At laparotomy, we suggest the use of physical barriers as the primary approach to adhesion prevention, after meticulous surgical technique (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatively,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      can be used. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical barriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expanded polytetrafluoroethylene (ePTFE, Gore-Tex Surgical Membrane) offers a significant reduction in adhesion formation; however, because it is nonabsorbable, a second-look procedure is needed for removal or the patient's consent is required for it to remain in situ. No data are available on the long-term effects of use of this product for pelvic surgery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Expanded polytetrafluoroethylene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At laparoscopy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      for adhesion reduction in patients undergoing adhesiolysis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Instillates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At present there is no evidence to support the use of systemic pharmacological agents for adhesion prevention. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Systemic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/1\">",
"      Lower AM, Hawthorn RJ, Ellis H, et al. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG 2000; 107:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/2\">",
"      Lower AM, Hawthorn RJ, Clark D, et al. Adhesion-related readmissions following gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study of 24 046 patients. Hum Reprod 2004; 19:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/3\">",
"      Al-Took S, Platt R, Tulandi T. Adhesion-related small-bowel obstruction after gynecologic operations. Am J Obstet Gynecol 1999; 180:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/4\">",
"      Al-Sunaidi M, Tulandi T. Adhesion-related bowel obstruction after hysterectomy for benign conditions. Obstet Gynecol 2006; 108:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/5\">",
"      Tulandi T, Collins JA, Burrows E, et al. Treatment-dependent and treatment-independent pregnancy among women with periadnexal adhesions. Am J Obstet Gynecol 1990; 162:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/6\">",
"      Practice Committee of the American Society for Reproductive Medicine, Society of Reproductive Surgeons. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. Fertil Steril 2007; 88:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/7\">",
"      Davey AK, Maher PJ. Surgical adhesions: a timely update, a great challenge for the future. J Minim Invasive Gynecol 2007; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/8\">",
"      Boys, F. The prophylaxis of peritoneal adhesions. A review of the literature. Surgery 1942; 11:l18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/9\">",
"      Levrant SG, Bieber EJ, Barnes RB. Anterior abdominal wall adhesions after laparotomy or laparoscopy. J Am Assoc Gynecol Laparosc 1997; 4:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/10\">",
"      Yesildaglar N, Koninckx PR. Adhesion formation in intubated rabbits increases with high insufflation pressure during endoscopic surgery. Hum Reprod 2000; 15:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/11\">",
"      Tulandi T, Hum HS, Gelfand MM. Closure of laparotomy incisions with or without peritoneal suturing and second-look laparoscopy. Am J Obstet Gynecol 1988; 158:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/12\">",
"      Stricker B, Blanco J, Fox HE. The gynecologic contribution to intestinal obstruction in females. J Am Coll Surg 1994; 178:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/13\">",
"      Farquhar C, Vandekerckhove P, Watson A, et al. Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev 2000; :CD000475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/14\">",
"      Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm adhesion barrier after intestinal resection. Dis Colon Rectum 2006; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/15\">",
"      Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril 1996; 66:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/16\">",
"      Haney AF, Hesla J, Hurst BS, et al. Expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7+) in preventing adhesions. Fertil Steril 1995; 63:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/17\">",
"      An expanded polytetrafluoroethylene barrier (Gore-Tex Surgical Membrane) reduces post-myomectomy adhesion formation. The Myomectomy Adhesion Multicenter Study Group. Fertil Steril 1995; 63:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/18\">",
"      Mettler L, Audebert A, Lehmann-Willenbrock E, et al. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil Steril 2004; 82:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/19\">",
"      Metwally M, Watson A, Lilford R, Vandekerckhove P. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev 2006; :CD001298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/20\">",
"      Rappaport WD, Holcomb M, Valente J, Chvapil M. Antibiotic irrigation and the formation of intraabdominal adhesions. Am J Surg 1989; 158:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/21\">",
"      Ricaurte E, Hilgers TW. Safety of intraperitoneal 32% dextran 70 as an antiadhesion adjuvant. J Reprod Med 1989; 34:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/22\">",
"      Sites CK, Jensen BA, Glock JL, et al. Transvaginal ultrasonographic assessment of Hyskon or lactated Ringer's solution instillation after laparoscopy: randomized, controlled study. J Ultrasound Med 1997; 16:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/23\">",
"      Rose BI, MacNeill C, Larrain R, Kopreski MM. Abdominal instillation of high-molecular-weight dextran or lactated Ringer's solution after laparoscopic surgery. A randomized comparison of the effect on weight change. J Reprod Med 1991; 36:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/24\">",
"      Tulandi T, Hilton J. Effect of intraperitoneal 32% dextran 70 on blood coagulation and serum electrolytes. J Reprod Med 1985; 30:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/25\">",
"      Weinans MJ, Kauer FM, Klompmaker IJ, Wijma J. Transient liver function disturbances after the intraperitoneal use of 32% dextran 70 as adhesion prophylaxis in infertility surgery. Fertil Steril 1990; 53:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/26\">",
"      Tulandi T. Transient edema after intraperitoneal instillation of 32% dextran 70. A report of five cases. J Reprod Med 1987; 32:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/27\">",
"      Brown CB, Luciano AA, Martin D, et al. Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. Fertil Steril 2007; 88:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/28\">",
"      Metwally M, Gorvy D, Watson A, Li TC. Hyaluronic acid fluid agents for the prevention of adhesions after fertility-preserving gynecological surgery: a meta-analysis of randomized controlled trials. Fertil Steril 2007; 87:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/29\">",
"      LeGrand EK, Rodgers KE, Girgis W, et al. Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model. J Invest Surg 1995; 8:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/30\">",
"      Montz FJ, Monk BJ, Lacy SM, Fowler JM. Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol Oncol 1993; 48:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26359/abstract/31\">",
"      Holschneider CH, Nejad F, Montz FJ. Immunomodulation with interleukin-10 and interleukin-4 compared with ketorolac tromethamine for prevention of postoperative adhesions in a murine model. Fertil Steril 1999; 71:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2891 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26359=[""].join("\n");
var outline_f25_47_26359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND BURDEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS OF ADHESION FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACH TO PREVENTION OF ADHESION FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical barriers and pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL BARRIERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sheets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Oxidized regenerated cellulose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hyaluronic acid sheets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Expanded polytetrafluoroethylene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Polyethylene glycol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Instillates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Icodextrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hyaluronic acid solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SYSTEMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoids, promethazine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2891|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/41/39581\" title=\"figure 1\">",
"      Efficacy of ePTFE and ORC in preventing adhesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26360="Epidemiology and risk factors for urinary tract infections in children";
var content_f25_47_26360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for urinary tract infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Nader Shaikh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Alejandro Hoberman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26360/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection (UTI) is a common and important clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal disease. Although children with pyelonephritis tend to present with fever, it is often difficult on clinical grounds to distinguish cystitis from pyelonephritis, particularly in young children (those younger than two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, we have defined UTI broadly here without attempting to distinguish cystitis from pyelonephritis. Acute cystitis in older children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link\">",
"     \"Acute cystitis in children older than two years and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of risk factors for UTI and renal scarring in a child presenting with fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinary symptoms is helpful in guiding diagnostic testing and management. The epidemiology and risk factors for UTI and renal scarring in children will be reviewed here. Clinical features, diagnosis, and management of UTI, and UTI in newborns (younger than one month of age) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the epidemiology of UTI is important in the evaluation of a child with suspected UTI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awareness of the prevalence of UTI in various subgroups of children enables the clinician to grossly estimate the probability of infection in the patient (ie, the pretest probability) (",
"    <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     In young children with fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of UTI in children &lt;2 years presenting with fever has been the subject of several large prospective studies and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Important points that emerged from these studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of UTI is approximately 7 percent in febrile infants and young children but varies by age,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      sex, and circumcision status.",
"     </li>",
"     <li>",
"      White children have a two- to fourfold higher prevalence of UTI than do black children.",
"     </li>",
"     <li>",
"      Girls have a two- to fourfold higher prevalence of UTI than do circumcised boys.",
"     </li>",
"     <li>",
"      White girls with a temperature of &ge;39&ordm;C have a UTI prevalence of 16 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approximate probability of having a UTI by demographic group, as determined by the above studies, is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     In older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pooled analysis of four studies that included children &lt;19 years (most of whom were older than two years) and had urinary symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever, the prevalence of UTI was 7.8 percent (95% CI 6.6-8.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Escherichia coli",
"    </em>",
"    is the most common bacterial cause of UTI; it accounts for approximately 85 percent of UTI in children. Other gram-negative bacterial pathogens include",
"    <em>",
"     Klebsiella",
"    </em>",
"    ,",
"    <em>",
"     Proteus",
"    </em>",
"    ,",
"    <em>",
"     Enterobacter",
"    </em>",
"    , and",
"    <em>",
"     Citrobacter",
"    </em>",
"    . Gram-positive bacterial pathogens include",
"    <em>",
"     Staphylococcus saprophyticus",
"    </em>",
"    ,",
"    <em>",
"     Enterococcus",
"    </em>",
"    , and, rarely,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    In a review of the clinical and laboratory characteristics of infants and children aged 1 week to 16 years with UTI caused by",
"    <em>",
"     E. coli",
"    </em>",
"    compared with other pathogens, non-",
"    <em>",
"     E. coli",
"    </em>",
"    UTI was associated with urinary tract anomalies, younger age, and previous antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viruses (eg, adenovirus, enteroviruses, Coxsackieviruses, echoviruses) and fungi (eg,",
"    <em>",
"     Candida",
"    </em>",
"    spp,",
"    <em>",
"     Aspergillus",
"    </em>",
"    spp,",
"    <em>",
"     Cryptococcus neoformans",
"    </em>",
"    , endemic mycoses) are uncommon causes of UTI in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Viral UTI are usually limited to the lower urinary tract. Risk factors for fungal UTI include immunosuppression and long-term use of broad-spectrum antibiotic therapy, and indwelling urinary catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute cystitis in children older than two years and adolescents\", section on 'Infectious causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacteriology of UTI, along with the observation that a minority (4 to 9 percent) of children with UTI are bacteremic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], is consistent with the hypothesis that most UTI beyond the newborn period are the result of ascending infection.",
"   </p>",
"   <p>",
"    Colonization of the periurethral area by uropathogenic enteric pathogens is the first step in the development of a UTI. The presence of pathogens on the periurethral mucosa, however, is not sufficient to cause UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/11\">",
"     11",
"    </a>",
"    ]. Pathogens attach to the uroepithelial cells via an active process mediated by glycosphingolipid receptors on the surface of epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Bacterial attachment recruits toll-like receptors (TLR), a family of transmembrane coreceptors involved in the recognition of pathogen-associated protein patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/14\">",
"     14",
"    </a>",
"    ]. TLR binding triggers a cytokine response, which generates a local inflammatory response.",
"   </p>",
"   <p>",
"    A variety of virulence factors enable bacteria to ascend into the bladder and kidney. The best-studied virulence factors in",
"    <em>",
"     E. coli",
"    </em>",
"    are pili, hair-like appendages on the cell surface. Bacteria possessing pili can adhere effectively to the uroepithelium and ascend into the kidney, even in children without vesicoureteral reflux (VUR). In the kidney, the bacterial inoculum generates an intense inflammatory response, which may ultimately lead to renal scarring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=see_link\">",
"     \"Bacterial adherence and other virulence factors for urinary tract infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HOST FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of host factors influence the predisposition to UTI in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of UTI is highest in boys younger than one year and girls younger than four years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lack of circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncircumcised male infants with fever have a four- to eightfold higher prevalence of UTI than circumcised male infants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two plausible mechanisms have been proposed to explain this difference:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mucosal surface of the uncircumcised foreskin is more likely to bind uropathogenic bacterial species than keratinized skin on a circumcised penis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/17\">",
"       17",
"      </a>",
"      ]. The keratinization of the mucosa is largely complete by one year of age and temporally coincides with the decreasing prevalence of UTI in boys.",
"     </li>",
"     <li>",
"      Partial obstruction of the urethral meatus by a tight foreskin may be the explanation for the higher incidence of UTI in uncircumcised boys [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In one study of uncircumcised male infants (&lt;7 months of age), inability to retract the foreskin to expose the urethral meatus was more common among boys with febrile UTI than among those without UTI (85 versus 42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/18\">",
"       18",
"      </a>",
"      ]. The tightness of the foreskin diminishes with time and is an infrequent finding after one year of age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the increased risk, most uncircumcised boys do not develop UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/20\">",
"     20",
"    </a>",
"    ]. A systematic review of randomized and observational studies of circumcision for the prevention of UTI found that 111 circumcisions would be needed to prevent one UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/16\">",
"     16",
"    </a>",
"    ]. Sensitivity analysis of a decision model for circumcision suggested that the decision to circumcise a boy hinges more heavily on the parents' values regarding pain than on the UTI prevalence or circumcision complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/21\">",
"     21",
"    </a>",
"    ]. This observation underscores the importance of respecting parental values as they decide whether to circumcise their sons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link\">",
"     \"Neonatal circumcision: Risks and benefits\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Female infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female infants have a two- to fourfold higher prevalence of UTI than male infants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/4\">",
"     4",
"    </a>",
"    ]. This has been presumed to be the result of the shorter female urethra. Because the incidence of UTI in male neonates is as high, if not higher, than in female neonates, the importance of the length of the urethra in the pathogenesis of UTI has been questioned. Alternatively, the propensity of bacterial attachment to the female periurethral mucosa may account for this difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Race/ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are not completely understood, white children have a two- to fourfold higher prevalence of UTI than do black children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-degree relatives of children with UTI are more likely to have UTI than individuals without such a history [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Adherence of bacteria may, in part, be genetically determined (eg, by the expression of blood group antigens on the surface of uroepithelial cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In addition, women with recurrent UTI have a higher density of receptors for",
"    <em>",
"     E. coli",
"    </em>",
"    in the periurethral area. On the other hand, individuals with mutations in the toll-like receptor (TLR) signaling pathway do not mount a significant inflammatory response, even when virulent bacteria are present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=see_link&amp;anchor=H6#H6\">",
"     \"Recurrent urinary tract infection in women\", section on 'Biologic or genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urinary obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with obstructive urologic abnormalities are at increased risk of developing UTI; stagnant urine is an excellent culture medium for most uropathogens. Predisposing obstructive abnormalities may be anatomic (posterior urethral valves, ureteropelvic junction obstruction), neurologic (eg, myelomeningocele with neurogenic bladder), or functional (eg, bowel and bladder dysfunction). (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Despite the increased risk of UTI in children with obstructive abnormalities, obstructive anatomic abnormalities are infrequent in children presenting with a first UTI (1 to 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/1,28-31\">",
"     1,28-31",
"    </a>",
"    ]. Urinary obstruction should be suspected when the patient has voiding problems (eg, daytime enuresis, dribbling of urine), other family members have had urologic abnormalities, when genitourinary abnormalities are detected on physical examination, or when symptoms do not respond to appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bowel and bladder dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel and bladder dysfunction, of which bladder dysfunction is a subset, is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An abnormal elimination pattern (frequent or infrequent voids, urgency, infrequent stools [constipation])",
"     </li>",
"     <li>",
"      Bladder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bowel incontinence",
"     </li>",
"     <li>",
"      Withholding maneuvers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bowel and bladder dysfunction usually presents in otherwise-healthy school-age children and may persist for months to years. The pathophysiology is varied but basically involves a behavioral or learned abnormality of function of the muscles of the pelvis, bladder,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sphincter. Although this condition is relatively common in children (its prevalence is approximately 15 percent), it is often underdiagnosed and undertreated by primary care clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Presenting manifestations include urgency, frequency, nocturnal enuresis, retention, incontinence, and urinary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel and bladder dysfunction is an important and often overlooked factor in the pathophysiology of UTI in children. Up to 40 percent of toilet-trained children with their first UTI and 80 percent of children with recurrent (three or more) UTI report symptoms of bowel and bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/28,35-37\">",
"     28,35-37",
"    </a>",
"    ]. Bowel and bladder dysfunction is also a risk factor for persistent VUR and renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/35,36,38-40\">",
"     35,36,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis usually is evident clinically. Initial evaluation and management should be initiated by the primary care clinician. Bowel and bladder dysfunction is a diagnosis of exclusion. Thus, a complete history and physical examination, a urinalysis, and a bladder ultrasound are usually obtained as part of the diagnostic evaluation (to rule out organic causes of incontinence, such as diabetes and neurogenic bladder). Chronic problems with elimination put these children at risk for significant psychosocial problems both at home and at school.",
"   </p>",
"   <p>",
"    Bowel and bladder dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=see_link\">",
"     \"Etiology and clinical features of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vesicoureteral reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. It is the most common urologic anomaly in children. Children with VUR are at increased risk for recurrent UTI. The clinical manifestations, management, and long-term implications of VUR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been widely believed that VUR constitutes a major risk factor for pyelonephritis and renal scarring in young children. However, the role of VUR in initiating pyelonephritis and scarring is poorly documented and may have been overstated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/41\">",
"     41",
"    </a>",
"    ]. An association between VUR and pyelonephritis has been demonstrated in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/1,42\">",
"     1,42",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/38,43\">",
"     38,43",
"    </a>",
"    ]. The role of VUR in renal scarring is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H18#H18\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Role in renal scarring and chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between sexual intercourse and UTI in females has been well documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949149#H899949149\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bladder catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of UTI increases with increasing duration of bladder catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BACTERIAL-HOST INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is indirect evidence that alteration of the normal periurethral flora promotes attachment of pathogenic bacteria as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study,",
"      <em>",
"       E. coli",
"      </em>",
"      and other gram-negative uropathogenic organisms were cultured more frequently from the urethras of uncircumcised boys than from those of circumcised boys, and bacterial colony counts were higher [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of preschool children with bacteriuria, recent treatment with antibiotics for upper respiratory infections was associated with an increased risk of febrile urinary tract infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of spermicidal condoms and spermicidal jelly with diaphragms has been independently associated with",
"      <em>",
"       E. coli",
"      </em>",
"      bacteriuria, suggesting that these agents predispose to UTI by altering the normal vaginal flora (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      and",
"      <em>",
"       Corynebacterium",
"      </em>",
"      spp) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In experimental studies in monkeys, the use of beta-lactam antibiotics (eg, penicillins and cephalosporins) disturbed the normal vaginal flora and promoted",
"      <em>",
"       E. coli",
"      </em>",
"      colonization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR RENAL SCARRING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal scarring, the loss of renal parenchyma between the calyces and the renal capsule, is a potential complication of UTI. Long-term consequences of renal scarring may include hypertension, decreased renal function, proteinuria, and end-stage renal disease.",
"   </p>",
"   <p>",
"    The development of renal scarring has been associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent febrile UTI (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H3#H3\">",
"       \"Long-term management and prevention of urinary tract infections in children\", section on 'Recurrent symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Delay in treatment of acute infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H6#H6\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Empiric therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bowel and bladder dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H5#H5\">",
"       \"Long-term management and prevention of urinary tract infections in children\", section on 'Children with bowel and bladder dysfunction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Obstructive malformations (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Chronic kidney disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link&amp;anchor=H29#H29\">",
"       \"Congenital ureteropelvic junction obstruction\", section on 'Outcome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      VUR (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H18#H18\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Role in renal scarring and chronic kidney disease'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Young age has been shown to be associated with scarring in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/50-55\">",
"     50-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the exception of age, each of the above factors is modifiable to some extent. The prevention of recurrent febrile UTI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H6#H6\">",
"     \"Long-term management and prevention of urinary tract infections in children\", section on 'Prevention of recurrent UTI in children without VUR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early initiation of UTI treatment requires that the diagnosis be considered even in the absence of symptoms referable to the urinary tract (eg, in the febrile infant or young child with or without a focus of infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modification of bowel and bladder dysfunction requires that it be recognized; presenting symptoms include urgency, enuresis, urinary retention, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26360/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Bowel and bladder dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Obstructive malformations are generally treated surgically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36502?source=see_link\">",
"     \"Management of posterior urethral valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link&amp;anchor=H20#H20\">",
"     \"Congenital ureteropelvic junction obstruction\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of VUR, which may be medical or surgical, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of urinary tract infection (UTI) in febrile children younger than two years varies from &lt;1 to 16 percent depending upon age, sex, circumcision status in boys, and",
"      <span class=\"nowrap\">",
"       race/ethnicity",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'In young children with fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of UTI in older children with urinary tract symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fever is approximately 8 percent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'In older children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Escherichia coli",
"      </em>",
"      is the most common bacterial cause of UTI. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of host factors influence the predisposition to UTI in children. These include genetic factors, urinary tract anomalies, bowel and bladder dysfunction, vesicoureteral reflux (VUR), sexual activity, and bladder catheterization in addition to those mentioned above for febrile young children. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Host factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bowel and bladder dysfunction is an important and often overlooked factor in the pathophysiology of UTI in children. It is characterized by an abnormal elimination pattern (frequent or infrequent voids, urgency, infrequent stools), bladder and or bowel incontinence, and withholding maneuvers. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bowel and bladder dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of renal scarring has been associated with recurrent febrile UTI, delay in treatment of acute infection, bowel and bladder dysfunction, obstructive malformations of the urinary tract, and VUR. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risk factors for renal scarring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/1\">",
"      Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/2\">",
"      Hoberman A, Chao HP, Keller DM, et al. Prevalence of urinary tract infection in febrile infants. J Pediatr 1993; 123:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/3\">",
"      Shaw KN, Gorelick M, McGowan KL, et al. Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics 1998; 102:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/4\">",
"      Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 2008; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/5\">",
"      Friedman S, Reif S, Assia A, et al. Clinical and laboratory characteristics of non-E. coli urinary tract infections. Arch Dis Child 2006; 91:845.",
"     </a>",
"    </li>",
"    <li>",
"     Wald ER. Cystitis and pyelonephritis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.554.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/7\">",
"      Sobel JD, Vazquez JA. Fungal infections of the urinary tract. World J Urol 1999; 17:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/8\">",
"      Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/9\">",
"      Smellie JM, Poulton A, Prescod NP. Retrospective study of children with renal scarring associated with reflux and urinary infection. BMJ 1994; 308:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/10\">",
"      Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999; 104:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/11\">",
"      Schlager TA, Whittam TS, Hendley JO, et al. Comparison of expression of virulence factors by Escherichia coli causing cystitis and E. coli colonizing the periurethra of healthy girls. J Infect Dis 1995; 172:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/12\">",
"      Godaly G, Bergsten G, Hang L, et al. Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. J Leukoc Biol 2001; 69:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/13\">",
"      Svanborg C, Bergsten G, Fischer H, et al. Uropathogenic Escherichia coli as a model of host-parasite interaction. Curr Opin Microbiol 2006; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/14\">",
"      Svanborg C, Frend&eacute;us B, Godaly G, et al. Toll-like receptor signaling and chemokine receptor expression influence the severity of urinary tract infection. J Infect Dis 2001; 183 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/15\">",
"      M&aring;rild S, Jodal U. Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age. Acta Paediatr 1998; 87:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/16\">",
"      Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child 2005; 90:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/17\">",
"      Fussell EN, Kaack MB, Cherry R, Roberts JA. Adherence of bacteria to human foreskins. J Urol 1988; 140:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/18\">",
"      Hiraoka M, Tsukahara H, Ohshima Y, Mayumi M. Meatus tightly covered by the prepuce is associated with urinary infection. Pediatr Int 2002; 44:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/19\">",
"      Shim YH, Lee JW, Lee SJ. The risk factors of recurrent urinary tract infection in infants with normal urinary systems. Pediatr Nephrol 2009; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/20\">",
"      American Academy of Pediatrics Task Force on Circumcision. Male circumcision. Pediatrics 2012; 130:e756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/21\">",
"      Chessare JB. Circumcision: is the risk of urinary tract infection really the pivotal issue? Clin Pediatr (Phila) 1992; 31:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/22\">",
"      M&aring;rild S, Wettergren B, Hellstr&ouml;m M, et al. Bacterial virulence and inflammatory response in infants with febrile urinary tract infection or screening bacteriuria. J Pediatr 1988; 112:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/23\">",
"      Lundstedt AC, Leijonhufvud I, Ragnarsdottir B, et al. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J Infect Dis 2007; 195:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/24\">",
"      Jantausch BA, Criss VR, O'Donnell R, et al. Association of Lewis blood group phenotypes with urinary tract infection in children. J Pediatr 1994; 124:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/25\">",
"      Sheinfeld J, Schaeffer AJ, Cordon-Cardo C, et al. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med 1989; 320:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/26\">",
"      Ragnarsd&oacute;ttir B, Samuelsson M, Gustafsson MC, et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/27\">",
"      Haraoka M, Hang L, Frend&eacute;us B, et al. Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 1999; 180:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/28\">",
"      Wan J, Kaplinsky R, Greenfield S. Toilet habits of children evaluated for urinary tract infection. J Urol 1995; 154:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/29\">",
"      Nuutinen M, Uhari M. Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol 2001; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/30\">",
"      Panaretto K, Craig J, Knight J, et al. Risk factors for recurrent urinary tract infection in preschool children. J Paediatr Child Health 1999; 35:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/31\">",
"      Elo J, Tallgren LG, Sarna S, et al. The role of vesicoureteral reflux in paediatric urinary-tract infection. Scand J Urol Nephrol 1981; 15:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/32\">",
"      Hellstr&ouml;m A, Hanson E, Hansson S, et al. Association between urinary symptoms at 7 years old and previous urinary tract infection. Arch Dis Child 1991; 66:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/33\">",
"      Shaikh N, Hoberman A, Wise B, et al. Dysfunctional elimination syndrome: is it related to urinary tract infection or vesicoureteral reflux diagnosed early in life? Pediatrics 2003; 112:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/34\">",
"      Feldman AS, Bauer SB. Diagnosis and management of dysfunctional voiding. Curr Opin Pediatr 2006; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/35\">",
"      Snodgrass W. Relationship of voiding dysfunction to urinary tract infection and vesicoureteral reflux in children. Urology 1991; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/36\">",
"      Naseer SR, Steinhardt GF. New renal scars in children with urinary tract infections, vesicoureteral reflux and voiding dysfunction: a prospective evaluation. J Urol 1997; 158:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/37\">",
"      Mazzola BL, von Vigier RO, Marchand S, et al. Behavioral and functional abnormalities linked with recurrent urinary tract infections in girls. J Nephrol 2003; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/38\">",
"      van Gool JD, Hj&auml;lm&aring;s K, Tamminen-M&ouml;bius T, Olbing H. Historical clues to the complex of dysfunctional voiding, urinary tract infection and vesicoureteral reflux. The International Reflux Study in Children. J Urol 1992; 148:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/39\">",
"      Koff SA, Wagner TT, Jayanthi VR. The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. J Urol 1998; 160:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/40\">",
"      Seruca H. Vesicoureteral reflux and voiding dysfunction: a prospective study. J Urol 1989; 142:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/41\">",
"      Garin EH, Campos A, Homsy Y. Primary vesicoureteral reflux: review of current concepts. Pediatr Nephrol 1998; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/42\">",
"      Arant BS Jr. Medical management of mild and moderate vesicoureteral reflux: followup studies of infants and young children. A preliminary report of the Southwest Pediatric Nephrology Study Group. J Urol 1992; 148:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/43\">",
"      Tamminen-M&ouml;bius T, Brunier E, Ebel KD, et al. Cessation of vesicoureteral reflux for 5 years in infants and children allocated to medical treatment. The International Reflux Study in Children. J Urol 1992; 148:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/44\">",
"      Wiswell TE, Miller GM, Gelston HM Jr, et al. Effect of circumcision status on periurethral bacterial flora during the first year of life. J Pediatr 1988; 113:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/45\">",
"      Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000; 343:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/46\">",
"      Winberg J, Herthelius-Elman M, M&ouml;llby R, Nord CE. Pathogenesis of urinary tract infection--experimental studies of vaginal resistance to colonization. Pediatr Nephrol 1993; 7:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/47\">",
"      Gleeson FV, Gordon I. Imaging in urinary tract infection. Arch Dis Child 1991; 66:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/48\">",
"      Martinell J, Claesson I, Lidin-Janson G, Jodal U. Urinary infection, reflux and renal scarring in females continuously followed for 13-38 years. Pediatr Nephrol 1995; 9:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/49\">",
"      Olbing H, Cla&euml;sson I, Ebel KD, et al. Renal scars and parenchymal thinning in children with vesicoureteral reflux: a 5-year report of the International Reflux Study in Children (European branch). J Urol 1992; 148:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/50\">",
"      Ditchfield MR, Summerville D, Grimwood K, et al. Time course of transient cortical scintigraphic defects associated with acute pyelonephritis. Pediatr Radiol 2002; 32:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/51\">",
"      Goldraich NP, Goldraich IH. Followup of conservatively treated children with high and low grade vesicoureteral reflux: a prospective study. J Urol 1992; 148:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/52\">",
"      Benador D, Benador N, Slosman D, et al. Are younger children at highest risk of renal sequelae after pyelonephritis? Lancet 1997; 349:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/53\">",
"      Lin KY, Chiu NT, Chen MJ, et al. Acute pyelonephritis and sequelae of renal scar in pediatric first febrile urinary tract infection. Pediatr Nephrol 2003; 18:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/54\">",
"      Ataei N, Madani A, Habibi R, Khorasani M. Evaluation of acute pyelonephritis with DMSA scans in children presenting after the age of 5 years. Pediatr Nephrol 2005; 20:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26360/abstract/55\">",
"      Pecile P, Miorin E, Romanello C, et al. Age-related renal parenchymal lesions in children with first febrile urinary tract infections. Pediatrics 2009; 124:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5988 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26360=[""].join("\n");
var outline_f25_47_26360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - In young children with fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - In older children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HOST FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lack of circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Female infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Race/ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urinary obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bowel and bladder dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bladder catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BACTERIAL-HOST INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RISK FACTORS FOR RENAL SCARRING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/16/269\" title=\"table 1\">",
"      Prevalence of UTI in febrile infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=related_link\">",
"      Acute cystitis in children older than two years and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=related_link\">",
"      Bacterial adherence and other virulence factors for urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=related_link\">",
"      Congenital ureteropelvic junction obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36502?source=related_link\">",
"      Management of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=related_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=related_link\">",
"      Patient information: Urinary tract infections in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26361="Oral lichen planus: Management and prognosis";
var content_f25_47_26361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral lichen planus: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Ginat W Mirowski, DMD, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Bethanee J Schlosser, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26361/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H172226975\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral lichen planus (oral LP) is a mucosal subtype of LP that presents with a variety of clinical features. Patients may develop reticular oral LP (white papules and plaques), erythematous (atrophic) oral LP (mucosal atrophy and red patches),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosive oral LP (erosions or frank ulcers) (",
"    <a class=\"graphic graphic_picture graphicRef76338 graphicRef54143 graphicRef62826 \" href=\"UTD.htm?3/54/3945\">",
"     picture 1A-C",
"    </a>",
"    ). Although reticular LP is usually asymptomatic, pain typically accompanies the erythematous and erosive forms of oral LP. The discomfort associated with these latter clinical subtypes is the reason why many patients seek treatment.",
"   </p>",
"   <p>",
"    The management and prognosis of oral LP will be reviewed here. The diagnosis of oral LP and information on other manifestations of LP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"     \"Lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=see_link&amp;anchor=H176463815#H176463815\">",
"     \"Overview of nail disorders\", section on 'Lichen planus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=see_link\">",
"     \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172226982\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there is no cure for oral LP, the primary goals of treatment are the alleviation of associated symptoms and the minimization of scarring from erosive lesions. Patients with asymptomatic reticular oral LP do not require treatment.",
"   </p>",
"   <p>",
"    Oral LP is managed with a combination of nonpharmacologic and pharmacologic measures, with some variability in the therapeutic approach based upon patient-specific factors (eg, disease extent, tolerance to treatment, comorbid disease) and treatment availability. In general, local therapy is preferred over systemic therapy to minimize the risk of serious adverse effects related to treatment.",
"   </p>",
"   <p>",
"    Topical corticosteroids are the first-line local treatment; additional options for local therapy include topical calcineurin inhibitors and intralesional corticosteroid injections. Systemic therapy is primarily reserved for patients who fail to respond sufficiently to local therapy or for patients with both oral LP and extraoral mucosal involvement.",
"   </p>",
"   <p>",
"    An important component of patient management is the recognition of symptoms that suggest ocular, laryngeal, esophageal, or vulvovaginal LP. Patients with signs or symptoms suggestive of such involvement should be referred to an appropriate specialist (ophthalmologist, otolaryngologist, gastroenterologist, or gynecologist) for an evaluation and the coordination of care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link&amp;anchor=H21977006#H21977006\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\", section on 'Extraoral findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172226989\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonpharmacologic measures may help to reduce morbidity associated with oral LP. Exposure to factors that may exacerbate the disease should be minimized. We typically encourage the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of good oral hygiene (brushing twice daily, flossing daily, professional dental cleaning every three to four months)",
"     </li>",
"     <li>",
"      Elimination of mechanical irritation from dental restorations, dental appliances, or sharp or malaligned teeth",
"     </li>",
"     <li>",
"      Avoidance of habits that cause trauma (eg, chewing on lips or mucosa)",
"     </li>",
"     <li>",
"      Cessation of smoking",
"     </li>",
"     <li>",
"      Minimization of consumption of acidic, salty, spicy, hot, sharp, or rough foods in patients in whom these factors seem to exacerbate symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with oral LP may find maintenance of oral hygiene challenging due to the discomfort elicited during oral care. However, the accumulation of dental plaque and calculus may cause local irritation and exacerbation of oral LP (Koebner phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with significant gingival involvement may be especially prone to periodontal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link&amp;anchor=H12#H12\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\", section on 'Periodontitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link&amp;anchor=H22#H22\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\", section on 'Medical effects of periodontal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We instruct patients to brush their teeth twice daily with a soft bristle toothbrush and bland toothpaste (ie, unflavored or at least devoid of mint or cinnamon flavoring). Use of a sonic toothbrush may provide effective cleaning while minimizing discomfort and tissue trauma. In addition, colorimetric plaque indicators may facilitate the identification of plaque that should be removed during brushing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be instructed to floss once daily with unflavored dental floss or tape. Professional dental cleanings should be performed every three to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172226996\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227003\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are the first-line treatment for oral LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. High potency or medium potency topical corticosteroids (potency groups 1 to 3) are typically used (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/5,9-14\">",
"     5,9-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227010\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of topical corticosteroids for oral LP was evaluated in a small placebo-controlled randomized trial. In the nine-week trial, 40 patients with reticular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosive oral LP were treated with either a group 3 potency topical corticosteroid (a 0.025% concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    in an adhesive base) or placebo. Both substances were applied at least six times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the 20 patients treated with fluocinonide, four (20 percent) had complete responses and 12 (60 percent) had good or partial responses to therapy. In contrast, no complete responses and only six partial responses (30 percent) occurred in the placebo-treated patients.",
"   </p>",
"   <p>",
"    Beneficial effects of treatment with topical corticosteroids have also been reported in several randomized trials that have compared individual corticosteroid therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/9,12-14\">",
"     9,12-14",
"    </a>",
"    ]. A systematic review of randomized trials that evaluated the efficacy of treatments for reducing pain due to oral LP found insufficient evidence to conclude superiority of any specific topical corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227017\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We usually prescribe a high potency topical corticosteroid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate 0.05%,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05%, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    propionate 0.05% gel or ointment, and instruct patients to dry the affected areas with gauze prior to application. The topical corticosteroid is applied three to four times per day using a fingertip or cotton-tipped applicator (eg, Q-tip). Eating or drinking should be avoided for at least 30 minutes after application. As symptoms improve, the frequency of application is reduced as tolerated.",
"   </p>",
"   <p>",
"    Other methods that have been used to administer topical corticosteroid therapy include the application of topical corticosteroids via gingival trays and the administration of topical corticosteroids as mouth rinses. Gingival trays may facilitate treatment for patients with significant gingival involvement (",
"    <a class=\"graphic graphic_picture graphicRef87467 \" href=\"UTD.htm?14/28/14786\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/15\">",
"     15",
"    </a>",
"    ]. Oral elixirs or suspensions (eg, 5 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [0.5",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL] used as a mouth rinse four to six times per day) are an option for patients with widespread oral disease and patients who have difficulty applying topical corticosteroids to the affected areas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical corticosteroids have also been formulated in adhesive dental bases with the intent of augmenting the response to treatment. However, superior efficacy of these formulations is not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227024\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis is a common side effect of intraoral topical corticosteroid use that can be prevented or treated with antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. In a small randomized trial, the addition of prophylactic miconazole to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    therapy did not affect the efficacy of treatment and was associated with a lower rate of oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not treat patients with oral LP prophylactically for oropharyngeal candidiasis. We monitor patients closely for symptoms and signs of candidiasis and perform confirmatory testing (usually with a potassium hydroxide [KOH] preparation) when the diagnosis is suggested. If a fungal culture is performed, the results should be carefully correlated with the clinical presentation since oral colonization with",
"    <em>",
"     Candida",
"    </em>",
"    species is common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Patients with dental appliances should remove and soak the appliances every night in dilute (0.02%)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite solution",
"    </a>",
"    , 0.12%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suspension (100,000",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic absorption resulting in adrenal suppression is an additional potential risk of topical corticosteroid use. However, the risk for adrenal suppression in patients treated for oral LP appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227031\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for patients who fail to respond to topical corticosteroids or who cannot tolerate topical corticosteroid therapy (eg, allergic contact mucositis, recurrent oropharyngeal candidiasis) include topical calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) and intralesional corticosteroids. A disadvantage of topical calcineurin inhibitors is the higher cost of these treatments in comparison to topical corticosteroids. Intralesional corticosteroid injection can be painful, may require multiple office visits, and has little available data on treatment efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227045\">",
"    <span class=\"h2\">",
"     Topical pimecrolimus and tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical calcineurin inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    can be effective for oral LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/22\">",
"     22",
"    </a>",
"    ]. Randomized trials that have compared the efficacy of these agents with topical corticosteroids indicate that pimecrolimus 1% can be at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    0.1% [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/23\">",
"     23",
"    </a>",
"    ] and tacrolimus 0.1% can be at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Pimecrolimus has not been directly compared to clobetasol or any other superpotent topical corticosteroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). A systematic review of randomized trials failed to find conclusive evidence of superiority of either class of agents for reducing pain due to oral LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227052\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy data on topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       Pimecrolimus",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; The efficacy of pimecrolimus in oral LP is supported by small randomized placebo-controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In a randomized trial in which 20 adults with erosive oral LP were treated with either pimecrolimus 1% or a vehicle cream twice daily for 30 days, 7 of 10 patients in the pimecrolimus group achieved complete clearance or marked improvement of lesions compared with only 2 of 10 patients in the vehicle group. In addition, a significantly greater reduction in the disease severity score was detected in the treatment group. The three patients who had not responded to pimecrolimus at the 30-day time point all achieved major improvement after an additional 30 days of treatment.",
"      <br/>",
"      <br/>",
"      The efficacy of four times daily application of pimecrolimus 1% cream and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide 0.1% paste were compared in a separate randomized trial of 40 patients with oral LP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/23\">",
"       23",
"      </a>",
"      ]. The two treatments had similar efficacy at two months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; The efficacy of topical tacrolimus is evident in randomized trials that have compared treatment with tacrolimus 0.1% ointment to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      0.05% ointment [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. Based upon these trials, tacrolimus appears to be at least as effective as clobetasol. The trials are reviewed in greater detail below:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a randomized trial in which 32 patients described as having moderate to severe oral LP were treated with application of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      four times per day for four weeks, statistically significant reductions in disease symptoms and signs occurred in both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/24\">",
"       24",
"      </a>",
"      ]. However, median scores for pain, burning sensation, and mucosal lesion extension at the end of therapy were significantly lower in the tacrolimus group.",
"     </li>",
"     <li>",
"      In a randomized trial of 30 patients with erosive LP treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      four times per day for two weeks, followed by a progressive taper to one time per day over a total of six weeks, the efficacy of the two agents was similar [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/25\">",
"       25",
"      </a>",
"      ]. Twenty-nine patients were analyzed and all but one patient who had received clobetasol responded to treatment. The differences in the percent reduction in lesion size at week six (83 percent for tacrolimus and 82 percent for clobetasol) and the percent reduction in pain score at week six (52 percent for tacrolimus and 38 percent for clobetasol) were not statistically significant.",
"     </li>",
"     <li>",
"      In a randomized trial in which 40 patients with symptomatic oral LP were treated with twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      for eight weeks, statistically significant reductions in the net clinical score were seen in both groups, and the score reductions were not significantly different between the groups [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, the differences in the rates of complete response (70 versus 40 percent, respectively) and complete or partial response (95 versus 90 percent, respectively) were not statistically significant among the tacrolimus and clobetasol groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227059\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in a similar manner as topical corticosteroids, instructing patients to apply medication to the affected areas after drying the sites with gauze. Treatment is applied two to four times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/22\">",
"     22",
"    </a>",
"    ] and patients should avoid eating and drinking for at least 30 minutes after application. The frequency of application is tapered as tolerated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     Pimecrolimus",
"    </a>",
"    is commercially available as a 1% cream.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is commercially available as both 0.03% or 0.1% ointment. The literature supports the use of the 0.1% concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227066\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burning sensation may occur after application of topical calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has been detected in the blood of patients treated with topical tacrolimus for oral LP, indicating that systemic absorption occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns have been raised regarding the potential for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    to increase the risk for cancer, evidenced by the US Food and Drug Administration&rsquo;s placement of a &ldquo;black box&rdquo; warning on these agents. However, a causative relationship between these agents and cancer has not been demonstrated to date and remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172229080\">",
"    <span class=\"h2\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide, in concentrations between 10 and 40",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    have been used successfully for oral LP. A study of 45 patients with ulcerative oral LP on the bilateral buccal mucosa in which only one side was treated with an intralesional corticosteroid injection (0.5 mL of triamcinolone acetonide 40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    found statistically significant reductions in signs and symptoms of oral LP within two weeks after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/31\">",
"     31",
"    </a>",
"    ]. On the treated side, the mean sizes of the areas affected by erythema or ulceration were reduced by 78 percent. In contrast, the untreated areas remained unchanged.",
"   </p>",
"   <p>",
"    In our experience, intralesional injection using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (5 to 10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    has been effective. Using 30-gauge &frac12; inch-length needles, we inject into the submucosa of recalcitrant oral LP lesions. Injections may be repeated every two to four weeks as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. If lesions fail to respond, we perform a biopsy to rule out malignant transformation.",
"   </p>",
"   <p>",
"    Side effects related to systemic absorption are risks of intralesional corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227073\">",
"    <span class=\"h2\">",
"     Topical cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have yielded variable results regarding the efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in oral LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/10,34,35\">",
"     10,34,35",
"    </a>",
"    ]. A small placebo-controlled randomized trial in which 16 patients with symptomatic oral LP used topical cyclosporine (5 mL of a 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    solution, swished for five minutes and then spit) or its vehicle three times daily supported the use of topical cyclosporine for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/34\">",
"     34",
"    </a>",
"    ]. After eight weeks, clinical improvement in erythema, erosions, reticulation, and pain were significantly greater in the treatment group than in the placebo group. All eight patients treated with cyclosporine had marked clinical improvement, whereas the eight patients in the vehicle group had no improvement or minimal benefit. In contrast, a randomized trial that compared cyclosporine given in a similar swish and spit regimen to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 1",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    paste found that both treatments resulted in only slight clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/35\">",
"     35",
"    </a>",
"    ]. There was no significant difference between the two groups in efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227080\">",
"    <span class=\"h1\">",
"     SEVERE AND REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral LP that cannot be adequately managed with topical therapy and extensive oral LP accompanied by extraoral mucosal involvement may respond to more aggressive treatment with systemic glucocorticoids. Less commonly, other systemic immunomodulatory agents are used for treatment. Data on the efficacy of systemic agents are primarily limited to small uncontrolled studies, case reports, and case series. The potential for serious drug-induced adverse effects is a concern for these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227087\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids have appeared to be effective for oral LP in small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one open-label study, 7 of 10 patients with oral LP who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40 to 80 mg once daily, or 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    achieved complete remission within 26 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/36\">",
"     36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We typically treat patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose similar to the dose above, with the goal of tapering to discontinuation within two to four weeks to minimize the risk for drug-related adverse effects. Because relapses frequently occur after the discontinuation of prednisone, we use topical corticosteroids to sustain improvement during tapering and after the cessation of systemic therapy. (See",
"    <a class=\"local\" href=\"#H172227003\">",
"     'Topical corticosteroids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although oral glucocorticoids may be useful for patients with resistant disease, most patients with oral LP do not require an oral glucocorticoid as initial therapy. This concept is supported by a study in which 49 adults with oral LP were treated with either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    or clobetasol without systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/38\">",
"     38",
"    </a>",
"    ]. Significant differences in patient outcomes were not detected.",
"   </p>",
"   <p>",
"    The adverse effects of systemic glucocorticoids are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227094\">",
"    <span class=\"h2\">",
"     Other systemic immunomodulatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional agents that may be useful in patients with severe or refractory oral LP based upon data from case reports and small retrospective studies include immunosuppressants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (50 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/41\">",
"     41",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (2.5 to 12 mg per",
"    <strong>",
"     week",
"    </strong>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/42\">",
"     42",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (1 to 2 g per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (50 to 200 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/42,46-48\">",
"     42,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227101\">",
"    <span class=\"h1\">",
"     ADDITIONAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been reported to be effective for oral LP include topical retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], oral retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/51-54\">",
"     51-54",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/42,55\">",
"     42,55",
"    </a>",
"    ], topical rapamycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/56\">",
"     56",
"    </a>",
"    ], oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (100 to 150 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/59\">",
"     59",
"    </a>",
"    ]. In a small randomized trial, oral circuminoids, components of the root tumeric (",
"    <em>",
"     Curcuma longa",
"    </em>",
"    ), reduced symptoms and signs of oral LP to a greater extent than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of oral LP with a variety of ultraviolet light-based modalities has been attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/61\">",
"     61",
"    </a>",
"    ]. Small uncontrolled studies and case reports have documented improvement in patients treated with psoralen plus ultraviolet A (PUVA) therapy, a 308 nm ultraviolet B (UVB) excimer laser, UVB phototherapy administered via a flexible fiber, and extracorporeal photochemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. Whether ultraviolet light therapy increases the risk for malignant transformation to oral squamous cell carcinoma, independent of the underlying risk inherent to oral LP, is unknown. Further study of the efficacy and safety of these interventions is necessary before these treatments can be routinely recommended. (See",
"    <a class=\"local\" href=\"#H172227122\">",
"     'Risk of oral squamous cell carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional physical interventions for oral LP have included surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/61\">",
"     61",
"    </a>",
"    ], photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], carbon dioxide lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], and cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172228883\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be added for pain management. In our experience, few oral LP patients have required more aggressive pain medication regimens.",
"   </p>",
"   <p>",
"    Local pain control with use of intraoral topical anesthetics (viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    2% solution, lidocaine 2% gel) can provide temporary benefit and improved oral intake. Potential risks include systemic absorption with potential toxicity and suppression of gag reflex with increased risk of aspiration.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    is not advised due to a rare risk of potentially fatal methemoglobinemia with even one application [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/71\">",
"     71",
"    </a>",
"    ]. The risk appears to be greatest in young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227108\">",
"    <span class=\"h1\">",
"     PATIENT SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral LP and concomitant chronic pain may be associated with increased risk for anxiety and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Patients who are experiencing these symptoms may benefit from referrals to psychological or psychiatric health services for help with coping skills and psychosocial support.",
"   </p>",
"   <p>",
"    Stress appears to alter a variety of endocrine and immune responses in patients with LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/74\">",
"     74",
"    </a>",
"    ]. Further study is necessary to determine whether stress is an exacerbating factor for oral LP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227115\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of oral LP is chronic, with waxing and waning severity. &nbsp;In a retrospective study of 808 Italian patients with oral LP who were followed for 6 to 304 months, sustained remission off-therapy was documented in only 2.5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227122\">",
"    <span class=\"h2\">",
"     Risk of oral squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the risk of malignant transformation of oral LP to oral squamous cell carcinoma (SCC) is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/75\">",
"     75",
"    </a>",
"    ]. Systematic interpretation of the available data is compromised by marked variability in study inclusion criteria. Reported rates for malignant transformation range from 0.4 to more than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/32,76-78\">",
"     32,76-78",
"    </a>",
"    ]. The highest risk for oral SCC may occur in patients with erythematous or erosive oral LP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26361/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the possibility that oral LP may increase risk for oral cancer, we encourage patients with oral LP to avoid activities known to increase the risk for oral cancer, such as smoking and alcohol use. The role of human papillomavirus infection in oral LP who develop SCC will require additional investigation. It is not known whether treatment of oral LP influences the risk of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172227129\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;We follow all patients with oral LP at least every 6 to 12 months, which allows for the assessment for early signs of malignancy. In addition to the oral exam, we palpate cervical lymph nodes to evaluate patients for the presence of lymphadenopathy. A biopsy to rule out oral cancer should be performed if signs suggestive of an oral cancer are detected (eg, leukoplakia, exophytic nodules, or persistent ulcers or erosions that fail to respond to therapy). The need for more frequent follow-up for disease management is dependent on disease activity and symptomatology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=see_link\">",
"       \"Patient information: Lichen planus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172228184\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral lichen planus (LP) is a subtype of LP that presents with reticular, erythematous (atrophic), or erosive lesions on the oral mucosa. Although reticular oral LP is often asymptomatic, patients with the erythematous and erosive subtypes of oral LP usually have associated pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link&amp;anchor=H106406489#H106406489\">",
"       \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical subtypes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of oral LP is implemented to improve symptoms and to minimize the risk for scarring from erosive lesions. Patients with asymptomatic reticular LP do not require treatment. (See",
"      <a class=\"local\" href=\"#H172226982\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic oral LP, we suggest treatment with a high potency topical corticosteroid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      propionate 0.05%) as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H172226996\">",
"       'First-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to improve adequately with topical corticosteroids or who cannot tolerate topical corticosteroids, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.1% ointment or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      1% cream (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Additional options for these patients include topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and intralesional corticosteroid injections. (See",
"      <a class=\"local\" href=\"#H172227031\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not respond adequately to local therapy may benefit from treatment with oral glucocorticoids or other systemic immunomodulatory therapies. (See",
"      <a class=\"local\" href=\"#H172227080\">",
"       'Severe and refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral LP is a risk factor for oral squamous cell carcinoma, though the magnitude of this risk remains unclear. A biopsy should be performed if patients develop lesions suspicious for oral malignancy. (See",
"      <a class=\"local\" href=\"#H172227122\">",
"       'Risk of oral squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with oral LP should be followed clinically at least every 6 to 12 months. More frequent follow-up may be indicated based upon disease activity and symptomatology. (See",
"      <a class=\"local\" href=\"#H172227129\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/1\">",
"      Holmstrup P, Schi&oslash;tz AW, Westergaard J. Effect of dental plaque control on gingival lichen planus. Oral Surg Oral Med Oral Pathol 1990; 69:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/2\">",
"      Ram&oacute;n-Fluix&aacute; C, Bag&aacute;n-Sebasti&aacute;n J, Mili&aacute;n-Masanet M, Scully C. Periodontal status in patients with oral lichen planus: a study of 90 cases. Oral Dis 1999; 5:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/3\">",
"      Azizi A, Rezaee M. Comparison of periodontal status in gingival oral lichen planus patients and healthy subjects. Dermatol Res Pract 2012; 2012:561232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/4\">",
"      Scattarella A, Petruzzi M, Ballini A, et al. Oral lichen planus and dental hygiene: a case report. Int J Dent Hyg 2011; 9:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/5\">",
"      Carbone M, Conrotto D, Carrozzo M, et al. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999; 5:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/6\">",
"      Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol 2012; 166:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/7\">",
"      Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/8\">",
"      Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; 2:CD008092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/9\">",
"      Carbone M, Arduino PG, Carrozzo M, et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. J Oral Pathol Med 2009; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/10\">",
"      Conrotto D, Carbone M, Carrozzo M, et al. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. Br J Dermatol 2006; 154:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/11\">",
"      Vo&ucirc;te AB, Schulten EA, Langendijk PN, et al. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol 1993; 75:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/12\">",
"      Campisi G, Giandalia G, De Caro V, et al. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial. Br J Dermatol 2004; 150:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/13\">",
"      Malhotra AK, Khaitan BK, Sethuraman G, Sharma VK. Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: A randomized comparative study. J Am Acad Dermatol 2008; 58:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/14\">",
"      Hegarty AM, Hodgson TA, Lewsey JD, Porter SR. Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol 2002; 47:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/15\">",
"      Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/16\">",
"      Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther 2010; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/17\">",
"      Lo Muzio L, della Valle A, Mignogna MD, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med 2001; 30:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/18\">",
"      Buajeeb W, Pobrurksa C, Kraivaphan P. Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/19\">",
"      Lodi G, Tarozzi M, Sardella A, et al. Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial. Br J Dermatol 2007; 156:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/20\">",
"      Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/21\">",
"      Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: a review. J Oral Sci 2008; 50:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/22\">",
"      Samycia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg 2012; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/23\">",
"      Gorouhi F, Solhpour A, Beitollahi JM, et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007; 57:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/24\">",
"      Corrocher G, Di Lorenzo G, Martinelli N, et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. J Clin Periodontol 2008; 35:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/25\">",
"      Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/26\">",
"      Sonthalia S, Singal A. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial. Int J Dermatol 2012; 51:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/27\">",
"      Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007; 143:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/28\">",
"      Volz T, Caroli U, L&uuml;dtke H, et al. Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 2008; 159:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/29\">",
"      Swift JC, Rees TD, Plemons JM, et al. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol 2005; 76:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/30\">",
"      Hodgson TA, Sahni N, Kaliakatsou F, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003; 13:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/31\">",
"      Xia J, Li C, Hong Y, et al. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med 2006; 35:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/32\">",
"      Carbone M, Arduino PG, Carrozzo M, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis 2009; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/33\">",
"      Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005; 11:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/34\">",
"      Eisen D, Ellis CN, Duell EA, et al. Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N Engl J Med 1990; 323:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/35\">",
"      Sieg P, Von Domarus H, Von Zitzewitz V, et al. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br J Dermatol 1995; 132:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/36\">",
"      Carbone M, Carrozzo M, Castellano S, et al. Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial. Minerva Stomatol 1998; 47:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/37\">",
"      Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol 1991; 72:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/38\">",
"      Carbone M, Goss E, Carrozzo M, et al. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med 2003; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/39\">",
"      Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol 2001; 81:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/40\">",
"      Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol 1996; 21:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/41\">",
"      Thorne JE, Jabs DA, Nikolskaia OV, et al. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol 2003; 136:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/42\">",
"      Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol 2007; 143:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/43\">",
"      Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol 2012; 167:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/44\">",
"      Dalmau J, Puig L, Ro&eacute; E, et al. Successful treatment of oral erosive lichen planus with mycophenolate mofetil. J Eur Acad Dermatol Venereol 2007; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/45\">",
"      Frieling U, Bonsmann G, Schwarz T, et al. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol 2003; 49:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/46\">",
"      Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol 2000; 136:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/47\">",
"      Dereure O, Basset-Seguin N, Guilhou JJ. Erosive lichen planus: dramatic response to thalidomide. Arch Dermatol 1996; 132:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/48\">",
"      Macario-Barrel A, Balguerie X, Joly P. [Treatment of erosive oral lichen planus with thalidomide]. Ann Dermatol Venereol 2003; 130:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/49\">",
"      Buajeeb W, Kraivaphan P, Pobrurksa C. Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/50\">",
"      Petruzzi M, De Benedittis M, Grassi R, et al. Oral lichen planus: a preliminary clinical study on treatment with tazarotene. Oral Dis 2002; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/51\">",
"      Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol 1986; 62:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/52\">",
"      Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985; 35:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/53\">",
"      Itin PH, Schiller P, Gilli L, Buechner SA. Isolated lichen planus of the lip. Br J Dermatol 1995; 132:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/54\">",
"      Brehmer F, Haenssle HA, Sch&ouml;n MP, Emmert S. Response of recalcitrant lichen planus to alitretinoin in 3 patients. J Am Acad Dermatol 2011; 65:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/55\">",
"      Eisen D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial. J Am Acad Dermatol 1993; 28:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/56\">",
"      Soria A, Agbo-Godeau S, Ta&iuml;eb A, Franc&egrave;s C. Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases. Dermatology 2009; 218:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/57\">",
"      Beck HI, Brandrup F. Treatment of erosive lichen planus with dapsone. Acta Derm Venereol 1986; 66:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/58\">",
"      Falk DK, Latour DL, King LE Jr. Dapsone in the treatment of erosive lichen planus. J Am Acad Dermatol 1985; 12:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/59\">",
"      Rasi A, Behzadi AH, Davoudi S, et al. Efficacy of oral metronidazole in treatment of cutaneous and mucosal lichen planus. J Drugs Dermatol 2010; 9:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/60\">",
"      Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol 2012; 66:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/61\">",
"      Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg 2008; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/62\">",
"      Lundquist G, Forsgren H, Gajecki M, Emtestam L. Photochemotherapy of oral lichen planus. A controlled study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/63\">",
"      K&ouml;llner K, Wimmershoff M, Landthaler M, Hohenleutner U. Treatment of oral lichen planus with the 308-nm UVB excimer laser--early preliminary results in eight patients. Lasers Surg Med 2003; 33:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/64\">",
"      Trehan M, Taylor CR. Low-dose excimer 308-nm laser for the treatment of oral lichen planus. Arch Dermatol 2004; 140:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/65\">",
"      Kassem R, Yarom N, Scope A, et al. Treatment of erosive oral lichen planus with local ultraviolet B phototherapy. J Am Acad Dermatol 2012; 66:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/66\">",
"      Guyot AD, Farhi D, Ingen-Housz-Oro S, et al. Treatment of refractory erosive oral lichen planus with extracorporeal photochemotherapy: 12 cases. Br J Dermatol 2007; 156:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/67\">",
"      Aghahosseini F, Arbabi-Kalati F, Fashtami LA, et al. Methylene blue-mediated photodynamic therapy: a possible alternative treatment for oral lichen planus. Lasers Surg Med 2006; 38:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/68\">",
"      Aghahosseini F, Arbabi-Kalati F, Fashtami LA, et al. Treatment of oral lichen planus with photodynamic therapy mediated methylene blue: a case report. Med Oral Patol Oral Cir Bucal 2006; 11:E126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/69\">",
"      van der Hem PS, Egges M, van der Wal JE, Roodenburg JL. CO2 laser evaporation of oral lichen planus. Int J Oral Maxillofac Surg 2008; 37:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/70\">",
"      de Magalhaes-Junior EB, Aciole GT, Santos NR, et al. Removal of oral lichen planus by CO2 laser. Braz Dent J 2011; 22:522.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm250024.htm (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/72\">",
"      Soto Araya M, Rojas Alcayaga G, Esguep A. Association between psychological disorders and the presence of Oral lichen planus, Burning mouth syndrome and Recurrent aphthous stomatitis. Med Oral 2004; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/73\">",
"      Rojo-Moreno JL, Bag&aacute;n JV, Rojo-Moreno J, et al. Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/74\">",
"      Krasowska D, Pietrzak A, Surdacka A, et al. Psychological stress, endocrine and immune response in patients with lichen planus. Int J Dermatol 2008; 47:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/75\">",
"      Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 2008; 14:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/76\">",
"      van der Meij EH, Mast H, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol 2007; 43:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/77\">",
"      Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol 2004; 40:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/78\">",
"      Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/79\">",
"      Parashar P. Oral lichen planus. Otolaryngol Clin North Am 2011; 44:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26361/abstract/80\">",
"      Hietanen J, Paasonen MR, Kuhlefelt M, Malmstr&ouml;m M. A retrospective study of oral lichen planus patients with concurrent or subsequent development of malignancy. Oral Oncol 1999; 35:278.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86851 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26361=[""].join("\n");
var outline_f25_47_26361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172228184\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172226975\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172226982\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172226989\">",
"      NONPHARMACOLOGIC MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172226996\">",
"      FIRST-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227003\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227010\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227017\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227024\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172227031\">",
"      SECOND-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227045\">",
"      Topical pimecrolimus and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227052\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227059\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172227066\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172229080\">",
"      Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227073\">",
"      Topical cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172227080\">",
"      SEVERE AND REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227087\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227094\">",
"      Other systemic immunomodulatory agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172227101\">",
"      ADDITIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172228883\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172227108\">",
"      PATIENT SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172227115\">",
"      PROGNOSIS AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227122\">",
"      Risk of oral squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172227129\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172228184\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/86851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/86851|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/30/20961\" title=\"picture 1A\">",
"      Lichen planus - oral Wickham striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/10/27808\" title=\"picture 1B\">",
"      Oral lichen planus - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/20/38209\" title=\"picture 1C\">",
"      Oral lichen planus - erosive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/28/14786\" title=\"picture 2\">",
"      Gingival tray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/86851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=related_link\">",
"      Gingivitis and periodontitis in adults: Classification and dental treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=related_link\">",
"      Lichenoid drug eruption (drug-induced lichen planus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=related_link\">",
"      Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=related_link\">",
"      Overview of nail disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=related_link\">",
"      Patient information: Lichen planus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26362="Medical management of patients after bariatric surgery";
var content_f25_47_26362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of patients after bariatric surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Robert F Kushner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Susan Cummings, MS, RD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/47/26362/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/47/26362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a chronic disorder that is increasing in prevalence in the United States and worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of therapy for obesity in adults\", section on 'Prevalence'",
"    </a>",
"    .) As the prevalence of obesity rises, the number of individuals with class III, high-risk obesity (body mass index [BMI] &gt;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    has increased substantially, and has contributed to an increase in bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/3\">",
"     3",
"    </a>",
"    ], with estimates of more than 175,000 procedures performed in the US in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, primary care clinicians are increasingly caring for patients who have undergone bariatric surgery (surgical therapy for obesity).",
"   </p>",
"   <p>",
"    The 1991 National Institutes of Health consensus development conference on gastrointestinal surgery for severe obesity recommended obesity surgery for those with a BMI &gt;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    as well as for those with a BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with significant comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the medical management of patients after bariatric surgery and common complications that may present to medical providers caring for these patients. The indications for bariatric surgery, the procedures themselves, and the surgical complications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CATEGORIES OF BARIATRIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgeries have traditionally been broken down into three categories: restrictive, malabsorptive, and combination procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restrictive procedures include the vertical banded gastroplasty (VBG), laparoscopic adjustable gastric banding (LAGB), and sleeve gastrectomy (SG).",
"     </li>",
"     <li>",
"      Malabsorptive procedures include the biliopancreatic diversion (BPD) and the duodenal switch operation",
"      <span class=\"nowrap\">",
"       (BPD/DS).",
"      </span>",
"      These procedures cause malabsorption of macro- and micronutrients by bypassing the majority of the small bowel absorptive surface area.",
"     </li>",
"     <li>",
"      Combination or mixed procedures, such as the Roux-en-Y gastric bypass (RYGB), combine restrictive and malabsorptive procedures and also lead to changes in neurohormonal pathways that regulate energy balance. Malabsorption after RYGB is primarily limited to micronutrients, and life-long vitamin and mineral supplementation is required to prevent development of deficiencies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative contributions of the mechanisms by which bariatric procedures result in effective, long-term weight loss are not entirely known, and may vary from individual to individual. These surgical procedures are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUTRITIONAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following bariatric surgery, patients experience significant improvements in medical comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and changes in hunger",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    satiety related to alterations in food pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diet after bariatric surgery is based on a staged approach with emphasis on texture and nutrient needs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/8\">",
"     8",
"    </a>",
"    ]. A large variation in food tolerances is seen, and patients who have undergone RYGB or LAGB benefit from well-planned dietary advancement, both to ensure proper healing of the surgery and to develop life-long healthy eating habits (",
"    <a class=\"graphic graphic_table graphicRef62266 \" href=\"UTD.htm?22/46/23277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50516 \" href=\"UTD.htm?37/33/38429\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The immediate postoperative diet recommendations emphasize hydration and protein intake. To avoid food impaction, patients are started on a liquid diet immediately following surgery. In RYGB, the gastrojejunostomy is routinely constructed with a relatively tight passage to provide restriction. The SG is also restrictive, and dietary advancement after SG is similar to that after RYBG. Even with LAGB, swelling is a common occurrence in the area of the circumferential band, predisposing to food impaction and further swelling. As these areas heal and diet tolerance is demonstrated, the diet is gradually advanced to solid foods.",
"   </p>",
"   <p>",
"    In the early postoperative period, patients should be advised to eat slowly (generally no more than 1 oz every 10 minutes), should stop eating if they feel full, and should not consume food and beverages at the same time (waiting 30 minutes after a meal to resume drinking). Vomiting and epigastric discomfort frequently occur if food is ingested too quickly, or when the patient eats more than the stomach pouch can hold. During the first few months after surgery, most patients learn to recognize the early satiety provided by a small gastric pouch. Overeating can result in vomiting, and most patients quickly learn to control portion sizes and food reactions. Guidance by an experienced bariatric dietitian is very helpful during the transition between diet stages.",
"   </p>",
"   <p>",
"    Since the small pouch of the RYGB is not capable of the same type of grinding as the native stomach, patients must be encouraged to chew food extensively to allow it to fully mix with saliva and to maximize the opportunity for absorption once it moves from the pouch to the small intestine. Similarly, although the grinding function of the antrum remains intact following SG and",
"    <span class=\"nowrap\">",
"     BPD/DS,",
"    </span>",
"    chewing food to the appropriate consistency facilitates passage of the food bolus through the gastric sleeve to the antrum itself. Thus, teaching patients to thoroughly chew their food and to practice mindful eating and avoiding distractions when eating is of primary importance.",
"   </p>",
"   <p>",
"    There is a common belief that the pouch increases in size over time. Careful studies have not been done, but endoscopic or surgical procedures are sometimes performed to tighten a dilated pouch or stoma in patients who are regaining weight. Learning to eat mindfully, planning, preparing and structuring meals and snacks are essential tools for lifelong success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Long-term eating habits",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Roux-en-Y gastric bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the changes in both the pouch size and gut hormone signaling, patients who have had Roux-en-Y gastric bypass (RYGB) need to recognize that initially they may not feel physical hunger, and when they do eat, they will experience early satiety. As their weight stabilizes and their need for external calories increases, their hunger and satiety awareness will change, food aversions and intolerances may develop:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hunger and satiety awareness will change as the RYGB changes physiology, and patients who have undergone this procedure must be taught how to pay attention to their hunger and satiety. Many patients express fear of again being able to eat more",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      of their hunger returning, and reassurance by their primary care providers that this is normal and that they need to pay attention and respond to both hunger and fullness is important. Learning to listen to their bodies' hunger and fullness is a new concept to many patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Learning how to choose healthy foods, not skipping meals, and planning and preparing meals and snacks on a daily basis is part of the new skills and goals all patients must learn. Patients may need continued reminders that the surgery has changed their body but not the environment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food aversions may develop in RYGB patients during the transition phase from liquids to soft foods to a full food diet, especially if there is prolonged vomiting associated with eating. For patients who enjoyed food variety prior to the surgery, the loss of food variety can result in anger and frustration. These patients will often complain that they experience anxiety and fear when eating. Reassurance and empathy is essential to help the patient overcome food intolerances. By six months, most patients are able to tolerate most foods, and tend to eat three small meals, with or without the inclusion of planned snacks, per day. If vomiting persists, anatomical etiologies (eg, ulcer, stricture) should be ruled out. Such patients with food aversions often express \"buyer's remorse\" and may request extensive investigations for problems with the gastric pouch. Reassurance about the ability of the pouch to tolerate a wide variety of foods with time is necessary.",
"     </li>",
"     <li>",
"      Food intolerances may develop, especially to red meat, and patients may choose a more vegetarian-based diet. Often, fresh fruits and vegetables are tolerated without a problem, resulting in a significant change in eating habits compared to preoperative eating habits. Frequent education, support and counseling sessions with a registered dietitian experienced with bariatric surgery are essential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sleeve gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is currently unclear how much impact the sleeve gastrectomy (SG) has on gut hormone signaling; there is conflicting evidence on its effects on ghrelin and there are no long-term data regarding nutrition recommendations. Most programs follow the same diet advancement and recommendations post-SG as they do post-RYGB.",
"   </p>",
"   <p>",
"    The mechanism of weight loss and resultant comorbidity improvement seen following sleeve gastrectomy may be related to gastric restriction or to neurohumoral changes observed following the procedure due to the gastric resection or some other unidentified factor(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nutritional recommendations for macronutrients after sleeve gastrectomy are similar to those after RYGB, and the protein intake should be between 0.8 to 1.0",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    ideal body weight per day, although exact needs are not clearly defined and may need to be individually assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laparoscopic adjustable gastric banding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone laparoscopic adjustable gastric banding (LAGB) will generally resume a normal diet soon after surgery, since the initial band is placed deflated. Rarely, patients may experience vomiting before the band is filled (usually six weeks post-band placement), if solid foods are ingested in large boluses or without adequate chewing.",
"   </p>",
"   <p>",
"    With gradual band tightening, which occurs periodically (four to six week intervals) during the first one to two years after surgery, patients begin to feel satiety at smaller meal sizes and learn to chew food more thoroughly.",
"   </p>",
"   <p>",
"    Aggressive tightening of the band may result in frequent vomiting, and may ultimately steer the patient to a maladaptive eating behavior. Over time, significant dilation of the esophagus similar to that seen in achalasia can occur. Furthermore, band patients with an overly-tight band may give up healthy solid foods and progressively rely on soft or liquid foods, which are better tolerated.",
"   </p>",
"   <p>",
"    Unfortunately, such foods tend to be calorie dense and nutrient poor (eg, milkshakes) and often do not provide adequate satiety as they rapidly empty from the pouch. When this occurs, weight loss can be suboptimal, and patients become frustrated with their inability to eat substantial foods.",
"   </p>",
"   <p>",
"    Removal of band fluid in a band that is too tight frequently allows patients to again eat healthy foods, and weight loss is often observed despite loosening of the band. If esophageal dilation is noted, a follow-up study should be obtained six to eight weeks later to confirm return of the esophagus to normal caliber. Persistence of nausea and vomiting after removal of fluid in the band may indicate band slippage or gastric prolapse, and should be investigated aggressively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common determinants for a band fill include assessment of level of hunger before meals, level of satiety after meals, amount of weight loss or gain, amount of food a patient is able to eat at one sitting, and if a patient is vomiting. A well-adjusted band, in combination with exercise and appropriate food choices, will initially lead to weight loss of approximately 1 to 2 lbs per week. Patients should be able to eat most solid foods; restriction should be just enough to allow smaller meals to cause and maintain satiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Biliopancreatic diversion/duodenal switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biliopancreatic diversion",
"    <span class=\"nowrap\">",
"     (BPD)/duodenal",
"    </span>",
"    switch",
"    <span class=\"nowrap\">",
"     (BPD/DS)",
"    </span>",
"    is a malabsorptive procedure for both macro- and micronutrients. These patients are at risk of protein malnutrition because of the great degree of malabsorption; protein intake of 1.5 g of",
"    <span class=\"nowrap\">",
"     protein/kg",
"    </span>",
"    ideal body weight per day may be required, making the average protein requirement per day approximately 90",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maintenance weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance",
"    weight while difficult to predict for an individual patient, is dependent on several factors, including the type of bariatric procedure performed, the severity of the initial obesity, adherence to appropriate eating and exercise behaviors, patient age, and functional status. Few patients will reach a normal weight (BMI of 25 or less), nor should this necessarily be considered an appropriate goal. Patients must be counseled regarding realistic weight-loss goals and encouraged to focus on other success measures, such as decreases in medications, resolution of comorbidities and quality of life changes.",
"   </p>",
"   <p>",
"    Long-term maintenance will depend on a patients' ability to withstand the food environment and to make a commitment to regular physical activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nutritional deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Micronutrient and mineral deficiencies can occur after bariatric surgery, particularly after malabsorptive or combination procedures, both because of inadequate intake of nutrients and because of alterations in the digestive anatomy due to the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/10\">",
"     10",
"    </a>",
"    ]. It is important to note that the standard RYGB does not cause malabsorption of macronutrients, only select micronutrients.",
"   </p>",
"   <p>",
"    Although micronutrient deficiencies are not commonly seen after LAGB, folate deficiency has been observed. Thus, folate should be routinely monitored, especially in women of childbearing age.",
"   </p>",
"   <p>",
"    The table gives recommended daily vitamin and mineral supplementation for all RYGB patients (",
"    <a class=\"graphic graphic_table graphicRef79014 \" href=\"UTD.htm?15/4/15438\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/8\">",
"     8",
"    </a>",
"    ]. Most programs recommend the same level of supplementation after the LAGB, however, it is unlikely that patients will need additional iron and vitamin B12 supplementation after LAGB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with vitamin D deficiency and secondary hyperparathyroidism, even in patients who have not undergone bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The vitamin D deficiency is speculated to be due to decreased sun exposure, insufficient intake, and reduced bioavailability of vitamin D from sequestration in fat.",
"   </p>",
"   <p>",
"    While vitamin D levels may increase after RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/14\">",
"     14",
"    </a>",
"    ], dietary calcium is best absorbed in the duodenum, where the highest concentration of calcium transporters is present. After RYGB, however, ingested food does not pass through the duodenum, and this may result in calcium deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/15\">",
"     15",
"    </a>",
"    ]. This can be further exacerbated by low intake of vitamin D in the diet. Thus, secondary hyperparathyroidism can develop or persist postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic poor calcium absorption, combined with inadequate supplementation, can lead to secondary hyperparathyroidism. Affected patients will show elevated levels of parathyroid hormone and normal to low serum calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/18\">",
"     18",
"    </a>",
"    ]. One study in 193 women in the United States found that postmenopausal women, African-American women, and those with a higher BMI were at increased risk of developing secondary hyperparathyroidism after RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteopenia and metabolic bone disease after RYGB have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/19\">",
"     19",
"    </a>",
"    ]. After RYGB, patients should be maintained on 1200-1500 mg calcium and at least 800 units of vitamin D daily to avoid metabolic bone disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of vitamin D deficiency and resistance\", section on 'Gastric bypass'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Micronutrient deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies in micronutrients are quite prevalent in patients with obesity before bariatric surgery, and these tend to persist after the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition to calcium and vitamin D deficiency leading to metabolic bone disease, RYGB patients have decreased absorption of iron, vitamin B12, fat-soluble vitamins (A, [D, as mentioned], E, K), thiamine, and folate.",
"   </p>",
"   <p>",
"    After RYGB, the food stream bypasses the majority of the stomach. This results in various alterations that can lead to vitamin B12 deficiency, which is common after RYGB, and can be corrected by supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/22\">",
"     22",
"    </a>",
"    ]. We suggest a daily oral dose of B12 of 500 to 1000 mcg. Peripheral neuropathy resulting from chronic vitamin B12 deficiency may not be reversible, and must be prevented by diligent laboratory monitoring and adequate replacement.",
"   </p>",
"   <p>",
"    Absorption of dietary iron is also reduced due to lower acid content in the gastric pouch and the bypass of its main sites of absorption (the duodenum and proximal jejunum). Iron deficiency and iron deficiency anemia are more commonly seen in menstruating women following RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/23\">",
"     23",
"    </a>",
"    ]. Prophylactic iron supplementation has been shown to lower the incidence of iron deficiency and subsequent anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If oral supplementation of vitamin B12 and iron is not adequate, intramuscular injections (vitamin B12) or intravenous infusions (iron) may be required to restore normal levels.",
"   </p>",
"   <p>",
"    Thiamine deficiency and Wernicke encephalopathy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/25\">",
"     25",
"    </a>",
"    ], particularly in patients with recurrent vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/26\">",
"     26",
"    </a>",
"    ]. The need for thiamine should be kept in mind in patients with persistent vomiting undergoing intravenous fluid repletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Copper and zinc deficiencies are frequent findings in biliopancreatic diversion patients, however, the frequency of copper deficiency and its clinical manifestations following RYGB is unclear. In a retrospective review of records of 136 patients who had undergone RYGB, 13 (10 percent) were found to have copper deficiency; a separate analysis from the same study followed 16 patients prospectively for two years, and three developed copper deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/27\">",
"     27",
"    </a>",
"    ]. Anemia was common in copper-deficient patients, and many were having mild-to-moderate symptoms such as fatigue and neuropathies that could have been related to copper deficiency (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of dietary trace minerals\", section on 'Copper'",
"    </a>",
"    ). Patients should be advised to take a daily multivitamin with 2 mg of copper.",
"   </p>",
"   <p>",
"    Zinc is absorbed in the small intestine, primarily in the jejunum, and patients who undergo long RYGB have a higher rate of zinc deficiency than those who undergo short RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/28\">",
"     28",
"    </a>",
"    ]. Zinc deficiency has been reported to occur in 6 to 40 percent of patients after RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Patients should be advised to take a daily multivitamin with 8 mg of elemental zinc. High levels of zinc supplementation (&gt;50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    can induce copper deficiency.",
"   </p>",
"   <p>",
"    The prevalence of micronutrient deficiency appears more common following RYGB, although deficiencies in fat-soluble vitamins can occur after LAGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should generally have their weight and blood pressure measured every four to six weeks until rapid weight loss diminishes, usually after 6 months, then again at 9 and 12 months, and annually thereafter. Patients maintained on antihypertensive or diabetic medications at discharge should be monitored closely for hypotension and hypoglycemia respectively, and medications should be adjusted accordingly.",
"   </p>",
"   <p>",
"    We suggest the following laboratory tests be performed at three months, six months, and annually thereafter, in general agreement with published guidelines for the perioperative nutritional, metabolic and nonsurgical support of the bariatric surgery patient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete Blood Count",
"     </li>",
"     <li>",
"      Electrolytes",
"     </li>",
"     <li>",
"      Glucose",
"     </li>",
"     <li>",
"      Iron studies, ferritin",
"     </li>",
"     <li>",
"      Vitamin B12",
"     </li>",
"     <li>",
"      Aminotransferases, alkaline phosphatase, bilirubin",
"     </li>",
"     <li>",
"      Albumin",
"     </li>",
"     <li>",
"      Lipid profile",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D, parathyroid hormone (PTH)",
"     </li>",
"     <li>",
"      Thiamine",
"     </li>",
"     <li>",
"      Folate",
"     </li>",
"     <li>",
"      Zinc",
"     </li>",
"     <li>",
"      Copper",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine postoperative visits are also an appropriate time to assess for evidence of the development of disordered eating (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Eating disorders'",
"    </a>",
"    below), which can lead to severe limitation of dietary intake, or psychological changes suggesting depression (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Depression and sadness'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of individuals go into obesity surgery with preexisting eating disordered behavior. Patients with disordered eating are unlikely to disclose these behaviors to their clinician unless they are solicited. Asking the patient to describe what they ate during the past 24 hours in a nonjudgemental and nonthreatening manner can often identify dysfunctional eating patterns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23175?source=see_link\">",
"     \"Dietary and nutritional assessment in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to maintain the weight loss that typically follows surgery, patients have to change their eating patterns dramatically. General normalization of eating behavior has been reported, characterized by fewer meals, less food consumed at each meal, less eating between meals, and less eating in response to strong emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Severe binge eating becomes virtually impossible following RYGB due to the severely restricted stomach.",
"   </p>",
"   <p>",
"    Despite this, patients with a preoperative history of eating disorders are more likely to have difficulty adjusting to the change in eating habits, and some may continue to have disordered eating patterns. Referral to an experienced psychologist can help unmask some of the underlying emotional issues associated with food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MEDICATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the immediate perioperative period, obesity-related medical comorbidities change dramatically. Many chronic medical conditions improve postoperatively with weight loss, which requires monitoring, and may require changes in the medications prescribed for those conditions.",
"   </p>",
"   <p>",
"    Pharmacokinetic data characterizing the impact of various bariatric surgeries on drug absorption and metabolism are scarce. RYGB, and other malabsorptive procedures that significantly exclude the proximal small intestine, decrease the surface area where most drug absorption occurs and may result in a reduction in systemic bioavailability. For example, a study of transplant patients who had previously undergone RYGB surgeries with differing Roux-limb lengths, documented decreased bioavailability and maximum drug concentrations of immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed, enteric-coated or extended-release preparations require a longer absorptive phase in the small intestine and are, therefore, more likely to have decreased bioavailability compared with immediate release forms, crushed tablets and liquids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/36\">",
"     36",
"    </a>",
"    ]. Postoperatively, patients should be transitioned to crushable (immediate release) or liquid preparations of medications. Medications requiring gastric acidity for dissolution, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    , are poorly absorbed, and substitution with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    is recommended. Close monitoring for effect of orally administered medications is recommended and alteration of dosing may be necessary.",
"   </p>",
"   <p>",
"    Solid dosage forms may be reintroduced after anastomotic sites are healed. However,",
"    <span class=\"nowrap\">",
"     tablet/capsule",
"    </span>",
"    size, dissolution and absorption sites in relation to type of surgery should be considered. For example, sustained release dosage forms are generally not recommended even after RYGB healing due to potentially decreased absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Consultation with a clinical pharmacist skilled in nutrition and medication therapy in malabsorptive states is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure often decreases to the normal range without continued therapy. Blood pressure should be measured at all postoperative visits. Hypotension is common in the early postoperative period, especially if there is poor fluid intake or persistent postoperative vomiting. In general, diuretic agents should initially be discontinued to avoid hypotension and electrolyte abnormalities.",
"   </p>",
"   <p>",
"    Hypertension is not always related to obesity and dietary interventions do not assure normalization of blood pressure. Patients should be monitored monthly until the blood pressure has stabilized, and patients may need to resume antihypertensive medications, but often at adjusted doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes should have frequent monitoring of blood glucose in the early postoperative period and should be managed with sliding scale insulin. Many diabetic patients have a decreased need for insulin after bariatric surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral sulfonylureas and meglitinides should be discontinued postoperatively as these medications can lead to hypoglycemia in diabetic patients after bariatric surgery.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is the safest oral drug in the postoperative period, since it is not associated with dramatic fluctuations in blood glucose, although some patients may experience gastrointestinal side effects. After RYGB, metformin should be administered in liquid form or immediate release preparation, which can be crushed.",
"   </p>",
"   <p>",
"    Discontinuation of all antidiabetic medications can be considered after RYGB when blood glucose normalizes and after the patient is eating.",
"   </p>",
"   <p>",
"    The decreased requirement for insulin and increased response to oral medications after bariatric surgery occurs for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average caloric intake ranges from 400 to 800",
"      <span class=\"nowrap\">",
"       kcal/day",
"      </span>",
"      for the first month, and thus the daily glycemic load is greatly reduced.",
"     </li>",
"     <li>",
"      Weight loss can be rapid and significant in the first month postoperatively (typically 20 to 40 lb [9 to 18 kg]) and this can lead to increased insulin sensitivity.",
"     </li>",
"     <li>",
"      Anatomic changes as a result of RYGB may result in changes in insulin leading to rapid postoperative improvements in glucose metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/38\">",
"       38",
"      </a>",
"      ]. Exposure of the distal jejunum to undigested nutrients elevates peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP). Glucose tolerance and insulin secretion occur independent of weight loss and resolution or improvement of type 2 diabetes occurs within days of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who underwent LAGB generally exhibit slower but gradual improvements in glucose metabolism and diabetes as they lose weight, particularly if they have long-standing diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    significant insulin requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications for gastroesophageal reflux (GERD) may be discontinued after RYGB and LAGB. Weight loss after these procedures tends to decrease intraabdominal pressure, leading to decreased acid reflux. Recurrent GERD symptoms after RYGB, particularly when accompanied by weight regain, should raise the possibility of a gastrogastric fistula between the gastric pouch and remnant, and should be investigated by an upper GI contrast study or CT scan and referred to the bariatric surgeon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H39#H39\">",
"     \"Complications of bariatric surgery\", section on 'Failure to lose weight and weight regain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss after bariatric surgery may lead to an increase in fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Cessation of menses should not be assumed to be due to rapid weight loss; in women of childbearing potential, cessation of menses is an indication for pregnancy testing.",
"   </p>",
"   <p>",
"    Concerns have been raised that bariatric surgery may interfere with the absorption of oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/41\">",
"     41",
"    </a>",
"    ]. A practice bulletin from the American College of Obstetricians and Gynecologists suggests that nonoral hormonal contraceptives should be considered in women who have undergone malabsorptive bariatric surgery and who desire hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest warning women that oral contraceptives may be less effective after malabsorptive procedures (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=see_link\">",
"     \"Contraception counseling for obese women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on antidepressants and other psychiatric medications should have these medications continued in the immediate postoperative period. Dramatic weight loss occurs in the first few months after bariatric surgery, and this can be associated with emotional lability. Maintaining patients on their psychiatric medications can help reduce this emotional lability. Although many patients experience enhanced self esteem and improved situational depression following weight loss, depression often requires continued treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to increased risk of bleeding from nonsteroidal anti-inflammatory drugs (NSAIDs), these medications should be discontinued postoperatively if possible. If analgesic or anti-inflammatory treatment is needed, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H28#H28\">",
"     \"Perioperative medication management\", section on 'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After RYGB, NSAID use is associated with an increased risk of marginal ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H30#H30\">",
"     \"Complications of bariatric surgery\", section on 'Marginal ulcers'",
"    </a>",
"    ). Although some clinicians recommend total avoidance of NSAIDs after RYGB, most patients who take NSAIDs after RYGB do not develop marginal ulcers. We do not feel that patients must permanently avoid this class of medication; as in all patients taking NSAIDs, the benefits must be weighed against the risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Weight based dosing of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight-based dosing of some common medications (eg, anti-infectives, sedatives and analgesics, neuromuscular blocking agents, anticoagulants, cardiovascular) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=see_link&amp;anchor=H9#H9\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Weight based dosing of medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative complications are classified into phases: phase one (one to six weeks), phase two (7 to 12 weeks), phase three (13 weeks to 12 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Weeks 1 to 6 (Phase 1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early complications (one to six weeks after surgery) are most often managed by the surgeons who performed the procedure. Complications of bariatric surgery include postoperative bleeding, staple line or anastomotic leak, bowel perforation, bowel obstruction, and wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/47\">",
"     47",
"    </a>",
"    ]. Wound infections are less common as more bariatric procedures are performed laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important medical complications after surgery include pulmonary embolism, myocardial infarction, pneumonia, and urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding after RYGB may involve intraluminal bleeding or intraabdominal bleeding from the surgical sites. Significant bleeding requiring transfusion or surgical repair is rare (&lt;2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Anastomotic leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the most severe complications of RYGB is a staple line leak at the gastrojejunal anastomosis. This occurs in approximately 2 to 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Anastomotic leak rates decline with increasing surgical volume and experience [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients typically present one to two days after surgery with symptoms that can include tachycardia and respiratory distress, and may progress to systemic sepsis and organ failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H21#H21\">",
"     \"Complications of bariatric surgery\", section on 'Leaks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute band obstruction can cause inability to tolerate saliva or liquids and is usually confirmed by UGI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow study. Acute obstruction is caused by placing a small band in a patient with a thick stomach. Obstruction can also occur from swelling if thick perigastric fat pads are not adequately dissected away prior to placing the band [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/53\">",
"     53",
"    </a>",
"    ]. Some patients may improve as the swelling subsides with time, but others may require removal (replacement with a larger band) or opening of the band [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAGB patients may develop bleeding as well. This occurs after acute band obstruction due to band malposition or swelling. Wound infections, bowel perforation, leakage or peritonitis are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Weeks 7 to 12 (Phase 2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weeks 7 to 12 are characterized by a distinct set of complications as the patient learns to adopt new ways of eating and becomes skilled at interpreting physiological feedback. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Early diet'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Psychological characteristics become a predominant factor in the postoperative visits, often characterized by food and weight obsessions. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Outcomes after surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Prolonged vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication in phase two after bariatric surgery is prolonged vomiting. A diet history recording dietary intake and portion sizes is important.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In LAGB patients, vomiting can occur as their diet is advanced to solid foods. Typically this is due to poor understanding of the mechanism of the surgery (purely restrictive), and is a consequence of inadequate chewing of food, eating too fast, large bite sizes, etc. Rarely, vomiting is due to the band being too tight.",
"     </li>",
"     <li>",
"      In RYGB patients, marginal ulcers at the anastomosis may cause pain, nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H30#H30\">",
"       \"Complications of bariatric surgery\", section on 'Marginal ulcers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In RYGB patients, a stomal stricture at the gastrojejunal anastomosis should be considered after dietary indiscretions and vomiting associated with bulimia are ruled out [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/56\">",
"       56",
"      </a>",
"      ]. The reported prevalence of stricture is approximately 4.6 percent. Patients with a stricture typically present six to seven weeks after surgery with symptoms of nausea, vomiting, early satiety, food intolerances (dysphagia to solid meals, or progressive dysphagia from solids to liquids), and postprandial pain in the gastric pouch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged vomiting may lead to dehydration, malnutrition, and an acute deficiency in thiamine, which can ultimately lead to Wernicke's encephalopathy. Thus, persistent vomiting in this phase should be evaluated promptly to avoid further complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow often detects narrowing at the gastrojejunal anastomosis, and a referral to a gastroenterologist for endoscopic dilatation should be made. Severe stenosis may require multiple endoscopic dilations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H29#H29\">",
"     \"Complications of bariatric surgery\", section on 'Stomal stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Dumping syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dumping syndrome occurs in approximately 50 percent of patients after RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/49\">",
"     49",
"    </a>",
"    ]. The same phenomenon does not appear to happen after LAGB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Postgastrectomy syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dumping syndrome is characterized by symptoms of nausea, shaking, diaphoresis, diarrhea, light-headedness, flushing, tachycardia and possibly syncope shortly after eating foods containing high amounts of refined sugars and when eating too fast. It is considered by some to be a positive effect after RYGB, especially in sweet-eaters, since it results in an aversion to consuming such foods. Patients who develop the dumping syndrome should be advised to avoid foods that provoke symptoms. Dumping syndrome is rarely severe enough to cause significant problems with nutritional intake [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Months 4 to 12 (Phase 3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of patients after bariatric surgery, months 4 to 12 are characterized by a significant change in eating habits, improvement in medical comorbidities, and continued weight loss.",
"   </p>",
"   <p>",
"    For a minority of patients, phase three is characterized by difficulty in adjustment to weight loss, food intolerances, self-destructive behaviors, and occasionally, requests for a reversal of the procedure. These patients tend to be time consuming for the treating clinician. Discerning the difference between psychological symptoms and physical symptoms can be difficult in this phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Cholelithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone formation is associated with rapid weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/59\">",
"     59",
"    </a>",
"    ], and the reported prevalence of gallstones at six months after RYGB is 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/60\">",
"     60",
"    </a>",
"    ]. A six-month course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    (300 mg twice daily) can reduce the incidence to 2 percent. Post-RYGB patients with symptomatic gallstones should undergo cholecystectomy. Because of the Roux-en-Y configuration of the foregut, it may not be possible to perform endoscopic retrograde cholangiopancreatography (ERCP) if choledocholithiasis occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H31#H31\">",
"     \"Complications of bariatric surgery\", section on 'Cholelithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gallstone formation is not commonly seen following LAGB, given the more gradual weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Small bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel obstruction (SBO) can result from postsurgical adhesions and from internal herniation from the Roux-en-Y anatomy in RYGB patients. Adhesions are generally rare following laparoscopic procedures. However, SBO from internal hernias after laparoscopic surgery can present with crampy abdominal pain, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/61\">",
"     61",
"    </a>",
"    ]. Radiologic studies (abdominal films or CT) may not reveal obvious bowel obstruction in patients with internal herniation, and thus a high index of suspicion and close consultation with the bariatric surgeon are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H33#H33\">",
"     \"Complications of bariatric surgery\", section on 'Internal hernias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Band erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although quite rare in most studies, the gastric band can erode through the gastric wall [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/53,62\">",
"     53,62",
"    </a>",
"    ]. Etiologies are felt to include poor surgical technique (placement of too tight a band over a thick stomach), aggressive band tightening, and chronic overeating with pouch dilation against a fixed band. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H43#H43\">",
"     \"Complications of bariatric surgery\", section on 'Band erosion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with band erosion may present with local infection involving the band port due to contamination of the band apparatus, or may complain of sudden band restriction and fullness. This is due to luminalization of the band, which allows food to pass through the remnant stomach around the band rather than through the banded portion. Upper gastrointestinal imaging or endoscopy will confirm the diagnosis. Once the diagnosis is established, the band needs to be removed, either surgically or endoscopically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Band slippage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For optimal functioning of the band, the position of the band has to be at the upper part of the stomach just below the gastroesophageal junction. The band is secured in position by suture fixation to the stomach wall at the time of the initial procedure.",
"   </p>",
"   <p>",
"    A small number of patients (3 to 6 percent) may develop slippage of the band leading to luminal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/53,62\">",
"     53,62",
"    </a>",
"    ]. Typically, these patients will present with symptoms of intermittent nausea, vomiting, progressive dysphagia, heartburn, and pain. If acute severe slippage occurs, the patient may experience complete gastric obstruction with a risk of ischemia and perforation. Band slippage may be related to missed and unrepaired hiatal hernia. Slippage requires surgical repair and repositioning of the band. Patients should be examined for hiatal hernia, and this must be repaired if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H44#H44\">",
"     \"Complications of bariatric surgery\", section on 'Band slippage and gastric prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     OUTCOMES AFTER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a complex disorder with a multitude of associated conditions and diseases that require careful follow-up. It is necessary to modify many of the standard medical assessment techniques and recognize the unique interaction of psychosocial and medical issues when caring for a patient after bariatric surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is rapid in the first six months after RYGB, averaging 10 to 15 lb (4.5 to 7 kg) per month. Thus, average weight loss at the six-month follow up visit is 60 to 80 lb (27 to 36 kg). Thereafter, the rate of weight loss tends to slow down to 5 to 7 lb (2 to 3 kg) per month, and total weight loss reaches a peak at 12 months post operatively, averaging 100 to 120 lb (45 to 54 kg).",
"   </p>",
"   <p>",
"    On average, a RYGB patient will achieve approximately 65 percent excess weight loss or 35 percent of initial body weight by two years. LAGB patients, on the other hand, tend to lose weight more steadily and slowly, over several years. At two years postoperatively, a typical band patient will lose 40 to 45 percent of the initial excess weight, or 25 percent of initial body weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical management of severe obesity\", section on 'Effectiveness of bariatric surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its superiority to other nonsurgical methods of weight loss for patients with severe, high-risk obesity, surgery still carries the risk of failed weight loss or weight regain. There is considerable controversy about the true long-term success of RYGB, since follow-up in many studies appears to be affected by outcome: patients who return to their prior eating habits after RYGB are less likely to follow up. When there is weight regain following RYGB, it typically begins 18 to 24 months postsurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that, although most patients do well initially, some ultimately fail to sustain their improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/66\">",
"     66",
"    </a>",
"    ]. Some band patients may not achieve significant weight loss even from the beginning. This highlights the importance of establishing a fundamental life-style change during the first one to two years after surgery in order to achieve long-term success in maintaining weight loss.",
"   </p>",
"   <p>",
"    Continuous snacking and consuming large quantities of soft or liquid foods have been associated with gradual weight regain regardless of the surgical procedure. Although meal size can be significantly reduced by surgical downsizing of the functional stomach, daily caloric intake can exceed the energy expenditure in patients who eat multiple meals and snacks throughout the day.",
"   </p>",
"   <p>",
"    A communication between the gastric pouch and the bypassed remnant stomach, or gastrogastric fistula, can lead to weight regain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/67\">",
"     67",
"    </a>",
"    ]. Additionally, chronic overeating can also result in pouch distension and stoma dilation, leading to positive net calorie balance and weight regain. If gastrogastric fistula is present in a patient with poor weight loss or gradual weight regain, a repair or closure by surgery or endoscopy is indicated. Newer endoscopic stomal narrowing procedures appear promising in reversing weight gain in patients with stoma dilation. Some researchers attribute the weight gain to physiological factors, but others claim that inadequate coping strategies are usually at the source of a patient's inability to maintain weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/66\">",
"     66",
"    </a>",
"    ]. Unfortunately, a small percentage of patients become \"grazers\" after bariatric surgery, and have poor weight loss.",
"   </p>",
"   <p>",
"    In a small percentage of patients, weight loss continues and severe disordered eating occurs, characterized by fear of eating and distorted body image. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .) Such patients should be referred to a skilled multidisciplinary team with experience in treating eating disorders for intensive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Physical function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most striking changes in medical symptoms and physical functioning after bariatric surgery are often difficult to quantify:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatigue improves, with an increase in energy level [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise habits improve with an increase in activities of daily living and recreational activities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Musculoskeletal and back pain improve or resolve in the majority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteoarthritis improves to a lesser degree, and is dependent on the degree of underlying bone and cartilage damage.",
"     </li>",
"     <li>",
"      The preoperative risk for an orthopedic procedure decreases, making subsequent surgery risks similar to those of lean controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep apnea tends to improve significantly, and refitting of the continuous positive airway pressure (CPAP) mask is often needed by six months postoperatively; CPAP pressure requirements usually decrease as well [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/73\">",
"       73",
"      </a>",
"      ]. At 12 months postoperatively, repeat overnight somnography is suggested to document the need for continued CPAP therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;After RYGB, there are psychological changes associated with the change in eating patterns, and these changes can cause significant dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Depression and sadness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extreme weight loss can lead to lethargy, depression, and other psychopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/74\">",
"     74",
"    </a>",
"    ]. Preoperatively, patients with severe obesity often use food for emotional reasons, and when they experience a small gastric pouch postoperatively they may grieve the loss of food. Displaced emotions can result in somatization with symptoms of nausea and vomiting.",
"   </p>",
"   <p>",
"    It is important that clinicians recognize the psychological aspect of the loss of food after RYGB, and reassure patients that the symptoms are related to the small gastric pouch size. Antidepressants often help to decrease the anxiety related to the grieving associated with the loss of food, although the use of antidepressants needs to be approached with an empathetic style.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23606411\">",
"    <span class=\"h3\">",
"     Alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be at increased risk for unhealthy use of alcohol after bariatric surgery. RYGB may alter the pharmacokinetics of alcohol, with more rapid absorption in the Roux limb leading to larger and more rapid rises in alcohol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/75-78\">",
"     75-78",
"    </a>",
"    ], and patients may note greater sensitivity to alcohol and more difficulty controlling drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective cohort study of 2458 patients undergoing bariatric surgery at 10 centers in the United States found that the prevalence of alcohol use disorder was similar in the year prior to bariatric surgery and the following year (7.6 versus 7.3 percent), but was higher in the second postoperative year (9.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/79\">",
"     79",
"    </a>",
"    ]. Risk factors for developing alcohol use disorder included male sex, younger age, regular alcohol consumption prior to surgery, and undergoing RYGB.",
"   </p>",
"   <p>",
"    Given this possible increased risk, clinicians caring for patients who have undergone bariatric surgery should pay particular attention to recommendations to periodically screen adults for unhealthy alcohol use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link&amp;anchor=H2654873#H2654873\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Effects of body changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid weight loss results in many psychological changes as the body shape changes. Several studies have shown increases in self-esteem, self-confidence, assertiveness, and expressiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Improvements are also typically seen in social interaction, sexual activity, and work performance.",
"   </p>",
"   <p>",
"    On the other hand, a significant number of patients discover that they have underdeveloped coping mechanisms in their new persona as a thin person. These patients may require psychological therapy to deal with issues of past sexual abuse, body image changes, and relationships with intimate partners.",
"   </p>",
"   <p>",
"    While weight loss improves the social lives of patients, they often have difficulty adjusting to dramatic changes in social circles. Patients previously involved in relationships with other people with obesity may find that changes in their lifestyle (ie, more activity, greater social contacts, changes in eating behavior) become incompatible with that of presurgical relationships.",
"   </p>",
"   <p>",
"    Social and business functions that revolve around food become awkward since patients have a significantly reduced stomach capacity. Family members, friends, coworkers, and acquaintances may also react with envy, or feel threatened following the patient's rapid weight loss.",
"   </p>",
"   <p>",
"    Patients may also feel resentment when they have suddenly improved social acceptance following weight loss; patients may not find it pleasant to be treated positively by people who once treated them badly because of their weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/64\">",
"     64",
"    </a>",
"    ]. These issues are often dealt with in long-term support groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Cosmetic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;When weight loss has stabilized, and if significant excess skin is present, the majority of patients request information about plastic surgery (most commonly removal of the abdominal pannus). Most insurance companies in the United States regard plastic surgery following bariatric surgery as cosmetic surgery, and will not cover it. In cases where the abdominal pannus is infected or excoriated, insurance coverage is possible, and insurance companies will typically require documentation of such complications.",
"   </p>",
"   <p>",
"    Although panniculectomy can be performed at the same time as bariatric surgery, a case series suggested that delaying surgery until after maximal weight loss may be safer and more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/82\">",
"     82",
"    </a>",
"    ]. Referral to a plastic surgeon experienced in the care of post-bariatric surgery patients may be helpful for those who wish to pursue surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery does not appear to be associated with adverse perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/41,83\">",
"     41,83",
"    </a>",
"    ], and pregnancy after surgery may be less likely to be complicated by gestational diabetes, hypertension, and fetal macrosomia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/40,42,43,84-87\">",
"     40,42,43,84-87",
"    </a>",
"    ]. There have, however, been rare case reports of maternal deaths from intestinal obstruction during pregnancy in women who had undergone RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=see_link\">",
"     \"Fertility and pregnancy after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A committee of the American College of Obstetricians and Gynecologists made the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/47/26362/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should be advised of the possible increased likelihood of pregnancy after weight loss (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Medication management'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Women should be advised to delay pregnancy for 12 to 18 months to avoid pregnancy during the period of rapid weight loss.",
"     </li>",
"     <li>",
"      Women with a gastric band should be monitored during pregnancy because the band may need to be adjusted.",
"     </li>",
"     <li>",
"      Women should be evaluated for nutritional deficiencies before pregnancy, and repleted during pregnancy with additional vitamin supplementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that, where available, women who become pregnant after bariatric surgery be referred to a high-risk obstetrical clinic for management and also be followed by an obstetric dietician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/55/3954?source=see_link\">",
"       \"Patient information: Care after weight loss surgery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After bariatric surgery, patients experience psychological changes, changes in medical comorbidities, and alterations in eating and physiologic feedback. They are also at risk for surgical complications (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients may develop vomiting, either as a result of food intolerances or from overeating. A rapid diet history may be helpful in distinguishing these etiologies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Early diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be evaluated every four to six weeks until rapid weight loss diminishes (typically after six months), then at 9 and 12 months, and annually thereafter. Review patterns of eating and assess for the development of psychological or eating disorders at each visit. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following laboratory tests be performed at three months, six months, and annually thereafter: complete blood count; electrolytes; glucose; iron studies, ferritin; vitamin B12; aminotransferases, alkaline phosphatase, bilirubin; albumin; lipid profile; 25-hydroxyvitamin D, parathyroid hormone (PTH); thiamine; folate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many chronic medical conditions improve postoperatively with weight loss; therefore, close monitoring of medications is important since requirements may change. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Medication management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cessation of menses should not be assumed to be due to rapid weight loss; in women of childbearing potential, cessation of menses is an indication for pregnancy testing. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early complications are typically managed by the surgical team and include bleeding, staple line leak, bowel perforation and obstruction, and wound infections. Medical complications include pulmonary embolism, myocardial infarction, pneumonia, and urinary tract infection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged vomiting can be due to the development of stomal stenosis or marginal ulcers in RYGB patients, and should be evaluated promptly to avoid further complications. Prolonged vomiting may lead to dehydration, malnutrition, and an acute deficiency in thiamine which can ultimately lead to Wernicke's encephalopathy. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prolonged vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dumping syndrome is characterized by symptoms of nausea, shaking, diaphoresis, diarrhea, light-headedness, flushing, tachycardia and possibly syncope. Dumping occurs immediately after eating foods containing high amounts of sugar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      from eating too fast. These symptoms occur in approximately 50 percent of patients after RYGB. Patients who develop the dumping syndrome should be advised to avoid foods that provoke symptoms. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Dumping syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are at risk for nutritional deficiencies after bariatric surgery. We suggest that patients receive vitamin and mineral supplementation as shown in the table (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef79014 \" href=\"UTD.htm?15/4/15438\">",
"       table 3",
"      </a>",
"      ). These patients should have nutritional labs monitored annually. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nutritional deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients can develop surgical problems, including gallstones and small bowel obstruction, which may be confused with food intolerances or somatization. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may experience many psychosocial and functional benefits from weight loss, but may also struggle with sadness at the loss of the ability to eat the volume or types of food previously consumed, as well as interpersonal implications of being a thinner person. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Outcomes after surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/1\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/2\">",
"      Balsiger BM, Murr MM, Poggio JL, Sarr MG. Bariatric surgery. Surgery for weight control in patients with morbid obesity. Med Clin North Am 2000; 84:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/3\">",
"      Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/4\">",
"      Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/5\">",
"      NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/6\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/7\">",
"      Sj&ouml;str&ouml;m L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond) 2008; 32 Suppl 7:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/8\">",
"      Mechanick, JI, Kushner, RF, Sugerman, HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &amp; Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity 2009; 17 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Metabolic and Bariatric Surgery position statement on sleeve gastrectomy as a bariatric procedure 2007; file://pugetsoundsurgicalcenter.com/sleeve_statement.pdf (Accessed on March 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/10\">",
"      Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg 2005; 15:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/11\">",
"      Hamoui N, Anthone G, Crookes PF. Calcium metabolism in the morbidly obese. Obes Surg 2004; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/12\">",
"      S&aacute;nchez-Hern&aacute;ndez J, Ybarra J, Gich I, et al. Effects of bariatric surgery on vitamin D status and secondary hyperparathyroidism: a prospective study. Obes Surg 2005; 15:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/13\">",
"      Hamoui N, Kim K, Anthone G, Crookes PF. The significance of elevated levels of parathyroid hormone in patients with morbid obesity before and after bariatric surgery. Arch Surg 2003; 138:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/14\">",
"      DiGiorgi M, Daud A, Inabnet WB, et al. Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding. Obes Surg 2008; 18:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/15\">",
"      Johnson JM, Maher JW, DeMaria EJ, et al. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg 2006; 243:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/16\">",
"      Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004; 89:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/17\">",
"      Ybarra J, S&aacute;nchez-Hern&aacute;ndez J, Gich I, et al. Unchanged hypovitaminosis D and secondary hyperparathyroidism in morbid obesity after bariatric surgery. Obes Surg 2005; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/18\">",
"      Youssef Y, Richards WO, Sekhar N, et al. Risk of secondary hyperparathyroidism after laparoscopic gastric bypass surgery in obese women. Surg Endosc 2007; 21:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/19\">",
"      De Prisco C, Levine SN. Metabolic bone disease after gastric bypass surgery for obesity. Am J Med Sci 2005; 329:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/20\">",
"      Flancbaum L, Belsley S, Drake V, et al. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. J Gastrointest Surg 2006; 10:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/21\">",
"      Tucker ON, Szomstein S, Rosenthal RJ. Nutritional consequences of weight-loss surgery. Med Clin North Am 2007; 91:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/22\">",
"      Ledoux S, Msika S, Moussa F, et al. Comparison of nutritional consequences of conventional therapy of obesity, adjustable gastric banding, and gastric bypass. Obes Surg 2006; 16:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/23\">",
"      Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 2008; 83:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/24\">",
"      Brolin RE, Gorman JH, Gorman RC, et al. Prophylactic iron supplementation after Roux-en-Y gastric bypass: a prospective, double-blind, randomized study. Arch Surg 1998; 133:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/25\">",
"      Singh S, Kumar A. Wernicke encephalopathy after obesity surgery: a systematic review. Neurology 2007; 68:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/26\">",
"      Aasheim ET. Wernicke encephalopathy after bariatric surgery: a systematic review. Ann Surg 2008; 248:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/27\">",
"      Gletsu-Miller N, Broderius M, Frediani JK, et al. Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond) 2012; 36:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/28\">",
"      Balsa JA, Botella-Carretero JI, G&oacute;mez-Mart&iacute;n JM, et al. Copper and zinc serum levels after derivative bariatric surgery: differences between Roux-en-Y Gastric bypass and biliopancreatic diversion. Obes Surg 2011; 21:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/29\">",
"      Gehrer S, Kern B, Peters T, et al. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study. Obes Surg 2010; 20:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/30\">",
"      Gong K, Gagner M, Pomp A, et al. Micronutrient deficiencies after laparoscopic gastric bypass: recommendations. Obes Surg 2008; 18:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/31\">",
"      Dalcanale L, Oliveira CP, Faintuch J, et al. Long-term nutritional outcome after gastric bypass. Obes Surg 2010; 20:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/32\">",
"      Mills MJ, Stunkard AJ. Behavioral changes following surgery for obesity. Am J Psychiatry 1976; 133:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/33\">",
"      Crisp AH, Kalucy RS, Pilkington TR, Gazet JC. Some psychosocial consequences of ileojejunal bypass surgery. Am J Clin Nutr 1977; 30:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/34\">",
"      Adami GF, Meneghelli A, Scopinaro N. Night eating and binge eating disorder in obese patients. Int J Eat Disord 1999; 25:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/35\">",
"      Rogers CC, Alloway RR, Alexander JW, et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008; 22:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/36\">",
"      Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006; 63:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/37\">",
"      Voelker M, Foster TG. Nursing challenges in the administration of oral antidepressant medications in gastric bypass patients. J Perianesth Nurs 2007; 22:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/38\">",
"      Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/39\">",
"      Cummings S, Apovian CM, Khaodhiar L. Obesity surgery: evidence for diabetes prevention/management. J Am Diet Assoc 2008; 108:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/40\">",
"      Martin LF, Finigan KM, Nolan TE. Pregnancy after adjustable gastric banding. Obstet Gynecol 2000; 95:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/41\">",
"      Marceau P, Kaufman D, Biron S, et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 2004; 14:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/42\">",
"      Guelinckx I, Devlieger R, Vansant G. Reproductive outcome after bariatric surgery: a critical review. Hum Reprod Update 2009; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/43\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol 2009; 113:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/44\">",
"      Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril 2009; 92:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/45\">",
"      Wilson JA, Romagnuolo J, Byrne TK, et al. Predictors of endoscopic findings after Roux-en-Y gastric bypass. Am J Gastroenterol 2006; 101:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/46\">",
"      Sasse KC, Ganser J, Kozar M, et al. Seven cases of gastric perforation in Roux-en-Y gastric bypass patients: what lessons can we learn? Obes Surg 2008; 18:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/47\">",
"      Schauer PR, Ikramuddin S. Laparoscopic surgery for morbid obesity. Surg Clin North Am 2001; 81:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/48\">",
"      Podnos YD, Jimenez JC, Wilson SE, et al. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 2003; 138:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/49\">",
"      Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/50\">",
"      Suter M, Giusti V, H&eacute;raief E, et al. Laparoscopic gastric banding. Surg Endosc 2003; 17:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/51\">",
"      Maher JW, Martin Hawver L, Pucci A, et al. Four hundred fifty consecutive laparoscopic Roux-en-Y gastric bypasses with no mortality and declining leak rates and lengths of stay in a bariatric training program. J Am Coll Surg 2008; 206:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/52\">",
"      Fullum TM, Aluka KJ, Turner PL. Decreasing anastomotic and staple line leaks after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2009; 23:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/53\">",
"      Ren CJ, Weiner M, Allen JW. Favorable early results of gastric banding for morbid obesity: the American experience. Surg Endosc 2004; 18:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/54\">",
"      O'Brien PE, Dixon JB. Laparoscopic adjustable gastric banding in the treatment of morbid obesity. Arch Surg 2003; 138:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/55\">",
"      Angrisani L, Furbetta F, Doldi SB, et al. Lap Band adjustable gastric banding system: the Italian experience with 1863 patients operated on 6 years. Surg Endosc 2003; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/56\">",
"      Ahmad J, Martin J, Ikramuddin S, et al. Endoscopic balloon dilation of gastroenteric anastomotic stricture after laparoscopic gastric bypass. Endoscopy 2003; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/57\">",
"      Barba CA, Butensky MS, Lorenzo M, Newman R. Endoscopic dilation of gastroesophageal anastomosis stricture after gastric bypass. Surg Endosc 2003; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/58\">",
"      Presutti RJ, Gorman RS, Swain JM. Primary care perspective on bariatric surgery. Mayo Clin Proc 2004; 79:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/59\">",
"      Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995; 98:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/60\">",
"      Villegas L, Schneider B, Provost D, et al. Is routine cholecystectomy required during laparoscopic gastric bypass? Obes Surg 2004; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/61\">",
"      Perugini RA, Mason R, Czerniach DR, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg 2003; 138:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/62\">",
"      Suter M, Calmes JM, Paroz A, Giusti V. A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. Obes Surg 2006; 16:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/63\">",
"      Shamblin JR, Shamblin WR. Bariatric surgery should be more widely accepted. South Med J 1987; 80:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/64\">",
"      Hsu LK, Benotti PN, Dwyer J, et al. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med 1998; 60:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/65\">",
"      Powers PS, Rosemurgy A, Boyd F, Perez A. Outcome of gastric restriction procedures: weight, psychiatric diagnoses, and satisfaction. Obes Surg 1997; 7:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/66\">",
"      Delin CR, Watts JM. Success in Surgical Intervention for Morbid Obesity: Is Weight Loss Enough? Obes Surg 1995; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/67\">",
"      Capella JF, Capella RF. Gastro-gastric fistulas and marginal ulcers in gastric bypass procedures for weight reduction. Obes Surg 1999; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/68\">",
"      Melissas J, Christodoulakis M, Schoretsanitis G, et al. Obesity-associated disorders before and after weight reduction by vertical banded gastroplasty in morbidly vs super obese individuals. Obes Surg 2001; 11:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/69\">",
"      Melissas J, Volakakis E, Hadjipavlou A. Low-back pain in morbidly obese patients and the effect of weight loss following surgery. Obes Surg 2003; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/70\">",
"      Peltonen M, Lindroos AK, Torgerson JS. Musculoskeletal pain in the obese: a comparison with a general population and long-term changes after conventional and surgical obesity treatment. Pain 2003; 104:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/71\">",
"      Melissas J, Kontakis G, Volakakis E, et al. The effect of surgical weight reduction on functional status in morbidly obese patients with low back pain. Obes Surg 2005; 15:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/72\">",
"      Parvizi J, Trousdale RT, Sarr MG. Total joint arthroplasty in patients surgically treated for morbid obesity. J Arthroplasty 2000; 15:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/73\">",
"      Lankford DA, Proctor CD, Richard R. Continuous positive airway pressure (CPAP) changes in bariatric surgery patients undergoing rapid weight loss. Obes Surg 2005; 15:336.",
"     </a>",
"    </li>",
"    <li>",
"     Keys, A. The biology of human starvation. University of Minnesota Press, Minneapolis 1950.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/75\">",
"      Hagedorn JC, Encarnacion B, Brat GA, Morton JM. Does gastric bypass alter alcohol metabolism? Surg Obes Relat Dis 2007; 3:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/76\">",
"      Klockhoff H, N&auml;slund I, Jones AW. Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. Br J Clin Pharmacol 2002; 54:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/77\">",
"      Maluenda F, Csendes A, De Aretxabala X, et al. Alcohol absorption modification after a laparoscopic sleeve gastrectomy due to obesity. Obes Surg 2010; 20:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/78\">",
"      Woodard GA, Downey J, Hernandez-Boussard T, Morton JM. Impaired alcohol metabolism after gastric bypass surgery: a case-crossover trial. J Am Coll Surg 2011; 212:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/79\">",
"      King WC, Chen JY, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA 2012; 307:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/80\">",
"      Leon GR, Eckert ED, Teed D, Buchwald H. Changes in body image and other psychological factors after intestinal bypass surgery for massive obesity. J Behav Med 1979; 2:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/81\">",
"      Solow C, Silberfarb PM, Swift K. Psychosocial effects of intestinal bypass surgery for severe obesity. N Engl J Med 1974; 290:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/82\">",
"      Acarturk TO, Wachtman G, Heil B, et al. Panniculectomy as an adjuvant to bariatric surgery. Ann Plast Surg 2004; 53:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/83\">",
"      Sheiner E, Levy A, Silverberg D, et al. Pregnancy after bariatric surgery is not associated with adverse perinatal outcome. Am J Obstet Gynecol 2004; 190:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/84\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 315, September 2005. Obesity in pregnancy. Obstet Gynecol 2005; 106:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/85\">",
"      Dixon JB, Dixon ME, O'Brien PE. Birth outcomes in obese women after laparoscopic adjustable gastric banding. Obstet Gynecol 2005; 106:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/86\">",
"      Weintraub AY, Levy A, Levi I, et al. Effect of bariatric surgery on pregnancy outcome. Int J Gynaecol Obstet 2008; 103:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/87\">",
"      Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/88\">",
"      Moore KA, Ouyang DW, Whang EE. Maternal and fetal deaths after gastric bypass surgery for morbid obesity. N Engl J Med 2004; 351:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/47/26362/abstract/89\">",
"      Loar PV 3rd, Sanchez-Ramos L, Kaunitz AM, et al. Maternal death caused by midgut volvulus after bariatric surgery. Am J Obstet Gynecol 2005; 193:1748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 587 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26362=[""].join("\n");
var outline_f25_47_26362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CATEGORIES OF BARIATRIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUTRITIONAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Long-term eating habits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Roux-en-Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laparoscopic adjustable gastric banding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Biliopancreatic diversion/duodenal switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maintenance weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nutritional deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Micronutrient deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MEDICATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonsteroidal anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Weight based dosing of medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Weeks 1 to 6 (Phase 1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Anastomotic leaks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Weeks 7 to 12 (Phase 2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Prolonged vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Dumping syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Months 4 to 12 (Phase 3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Cholelithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Small bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Band erosion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Band slippage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      OUTCOMES AFTER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Physical function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Depression and sadness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23606411\">",
"      - Alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Effects of body changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Cosmetic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23277\" title=\"table 1\">",
"      Diet stages RYGBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38429\" title=\"table 2\">",
"      Diet stages LAGB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/4/15438\" title=\"table 3\">",
"      Supplementation after RYGB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 4\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23175?source=related_link\">",
"      Dietary and nutritional assessment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=related_link\">",
"      Fertility and pregnancy after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/55/3954?source=related_link\">",
"      Patient information: Care after weight loss surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_47_26363="Diagnosis of Behcets disease";
var content_f25_47_26363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for Behcet's disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Required features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Recurrent oral ulceration",
"       </td>",
"       <td>",
"        Aphthous (idiopathic) ulceration, observed by physician or patient, with at least three episodes in any 12 month period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Plus any two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent genital ulceration",
"       </td>",
"       <td>",
"        Aphthous ulceration or scarring, observed by physician or patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eye lesions",
"       </td>",
"       <td>",
"        Anterior or posterior uveitis cells in vitreous in slit lamp examination; or retinal vasculitis documented by ophthalmologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin lesions",
"       </td>",
"       <td>",
"        Erythema nodosum-like lesions observed by physician or",
"patient; papulopustular skin lesions or pseudofolliculitis with",
"characteristic acnelform nodules observed by physician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pathergy test",
"       </td>",
"       <td>",
"        Interpreted at 24 to 48 hours by physician",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335:1078.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26363=[""].join("\n");
var outline_f25_47_26363=null;
var title_f25_47_26364="Causes of rhinitis";
var content_f25_47_26364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of rhinitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Allergic rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seasonal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perennial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Nonallergic rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasomotor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gustatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonallergic rhinitis with eosinophilia syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mixed rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Occupational rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Rhinitis medicamentosa",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nasal decongestant sprays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intranasal cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Systemic medication-induced rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Erectile dysfunction drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Some antihypertensives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aspirin and other NSAIDs (more prevalent among patients with asthma and/or chronic rhinosinusitis with nasal polyposis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Some antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Some benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Atrophic rhinitis",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Systemic diseases",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Midline granuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immotile cilia syndromes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26364=[""].join("\n");
var outline_f25_47_26364=null;
var title_f25_47_26365="A practical guide for using CBT to treat somatization";
var content_f25_47_26365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F66467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F66467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A practical guide for treating somatization with cognitive-behavioral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Principles and tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explore beliefs",
"       </td>",
"       <td>",
"        Ask patients what they believe is causing their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Define goals",
"       </td>",
"       <td>",
"        Define goals, eg, take responsibility for one's health or improved functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral analysis",
"       </td>",
"       <td>",
"        Analyze behavior to determine antecedents and consequences (ABC: antecedent, behavior, consequence). Ask about thoughts, behaviors, emotions, and situations that precede, accompany, and follow the symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diary",
"       </td>",
"       <td>",
"        The patient should use a diary to record symptoms, rate their severity, describe the situation during which a symptom occurred, describe how they felt at the time, and what they were thinking at the time. These entries are reviewed during treatment sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family",
"       </td>",
"       <td>",
"        The spouse or parents should be invited to attend one or more treatment sessions so they understand the treatment approach. Family members should be directed to stop their responses and accommodations to symptoms that are performed out of concern but which ultimately serve to reinforce the illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavior first",
"       </td>",
"       <td>",
"        The focus of treatment is changing cognitions and behaviors. It is easier to first change behaviors, especially for those patients who are less psychiatrically minded or more resistant to psychiatric explanations of their illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce maladaptive behavior",
"       </td>",
"       <td>",
"        Behavioral change starts with reducing avoidance behavior and other maladaptive behavioral responses to symptoms. This can reduce the frequency and intensity of symptoms, reduce disability, and help facilitate cognitive changes. In addition, clinicians and patients need to decide which adaptive behaviors to increase. These should be clearly specified, realistically attainable, and of value to the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incremental change",
"       </td>",
"       <td>",
"        Behavioral change is approached in a gradual way, with graded increases in desired activities. The difference between current behavior and the desired goals is assessed, and then broken down into manageable steps.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practice",
"       </td>",
"       <td>",
"        The clinician should warn the patient that each increase in previously avoided behavior could cause a transient increase in symptoms. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relaxation",
"       </td>",
"       <td>",
"        Teach relaxation techniques to increase the ability to bear with symptoms, reduce stress, and develop pleasant bodily sensations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social skills",
"       </td>",
"       <td>",
"        Provide social skills training.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regulate emotions",
"       </td>",
"       <td>",
"        Teach patients how to regulate their emotions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive change",
"       </td>",
"       <td>",
"        Cognitive change begins with identifying the patient's thoughts and beliefs about bodily sensations and physical symptoms. The clinician then asks the patient to consider alternative explanations and interpretations of symptoms. Patients record their thoughts about symptoms and practice challenging them by producing and recording more benign explanations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychoeducation",
"       </td>",
"       <td>",
"        Provide psychoeducation about somatization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Realistic health concept",
"       </td>",
"       <td>",
"        Help the patient develop a realistic health concept. Challenge faulty assumptions, such as the idea that one must be in perfect health in order to function, or that any bodily sensation is pathologic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restructure cognitions",
"       </td>",
"       <td>",
"        Aim to restructure cognitions to accept the role of psychiatric factors in somatization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstrate role of psychiatric factors",
"       </td>",
"       <td>",
"        Conduct exercises to demonstrate the role of psychiatric factors in health. Biofeedback experiments can help patients understand how their somatic preoccupation perpetuates their symptoms and disability. As an example, if the patient focuses on a normal bodily sensation such as the heartbeat, this will reveal an increase in its apparent intensity. The value of distraction as a method of symptom control can then be demonstrated. These experiments provide personal evidence the patient can use in reconsidering&nbsp;a general medical condition&nbsp;as the explanation of their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Well-being",
"       </td>",
"       <td>",
"        Address problems affecting well-being, such as difficulties in relationships and at work, cognitive misattributions, and emotional state.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Bornschein S, Forstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.",
"       </li>",
"       <li>",
"        Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26365=[""].join("\n");
var outline_f25_47_26365=null;
var title_f25_47_26366="Causes of abdominal pain by location";
var content_f25_47_26366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70233%7EGAST%2F60310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70233%7EGAST%2F60310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of abdominal pain by location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Right upper quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Biliary colic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Budd-Chiari syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia/empyema pleurisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subdiaphragmatic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Right lower quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salpingitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ectopic pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inguinal hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrolithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesenteric adenitis (yersina)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Epigastric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroesophageal reflux disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pericarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ruptured aortic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Periumbilical",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Early appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bowel obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ruptured aortic aneurysm",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Left upper quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic infarct",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastric ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Left lower quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salpingitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ectopic pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inguinal hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrolithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diffuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesenteric ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metabolic (eg, DKA, porphyria)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial Mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bowel obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peritonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected extraabdominal causes of acute abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial ischemia and infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Thoracic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pleurodynia, Bornholm's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolism and infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Empyema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophageal spasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophageal rupture (Boerhaave's syndrome)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiculitis: spinal cord or peripheral nerve tumors, degenerative arthritis of spine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abdominal epilepsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tabes dorsalis (tertiary syphilis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus (ketoacidosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porphyria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute adrenal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperlipidemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperparathyroidism",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemolytic anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Henoch-Sch&ouml;nlein purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypersensitivity reactions: insect bites, reptile venoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals and corrosives (eg, lead or iron)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes zoster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Typhoid fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_left\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Muscular contusion, hematoma, or tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Narcotic withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial Mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychiatric disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heat stroke",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glasgow RE, Mulvihill SJ. Abdominal pain, including the acute abdomen. In: Gastrointestinal and Liver Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds). WB Saunders, Philadelphia 1998, p.80. Copyright &copy; 1998 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26366=[""].join("\n");
var outline_f25_47_26366=null;
var title_f25_47_26367="Ovarian cancer ultrasound";
var content_f25_47_26367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant ovarian mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of a complex, malignant ovarian mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge Londono, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_47_26367=[""].join("\n");
var outline_f25_47_26367=null;
